| [
|
| {
|
| "asset": "abrocitinib",
|
| "nct_id": "NCT06807268",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-05-02",
|
| "conditions": "Eczema",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "abrocitinib",
|
| "nct_id": "NCT06807281",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2032-02-22",
|
| "conditions": "Atopic Dermatitis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "acasunlimab",
|
| "nct_id": "NCT06635824",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-07-30",
|
| "conditions": "PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Genmab",
|
| "company_name": "GENMAB A/S",
|
| "ticker": "GMAB"
|
| },
|
| {
|
| "asset": "alectinib",
|
| "nct_id": "NCT03178552",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-10-31",
|
| "conditions": "Non-Small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Hoffmann-La Roche",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "alectinib",
|
| "nct_id": "NCT03768063",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2028-07-05",
|
| "conditions": "Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Hoffmann-La Roche",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "alectinib",
|
| "nct_id": "NCT05170204",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2030-06-16",
|
| "conditions": "Non-Small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Hoffmann-La Roche",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "alectinib",
|
| "nct_id": "NCT05722886",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-10",
|
| "conditions": "Haematological Malignancy; Solid Tumour",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Cancer Research UK",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "alectinib",
|
| "nct_id": "NCT05770037",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-10",
|
| "conditions": "Haematological Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Anaplastic Large Cell Lymphoma; Lymphoma; Renal Cell Carcinoma; Neuroblastoma; Solid Tumour",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Cancer Research UK",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "alectinib",
|
| "nct_id": "NCT06765109",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-12",
|
| "conditions": "Non-small Cell Lung Cancer; Anaplastic Lymphoma Kinase-positive",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Nuvalent Inc.",
|
| "company_name": "Nuvalent, Inc.",
|
| "ticker": "NUVL"
|
| },
|
| {
|
| "asset": "anifrolumab",
|
| "nct_id": "NCT04877691",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2025-08-22",
|
| "conditions": "Systemic Lupus Erythematosus",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "anifrolumab",
|
| "nct_id": "NCT05138133",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-02-26",
|
| "conditions": "Lupus Nephritis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "anifrolumab",
|
| "nct_id": "NCT05835310",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-10-05",
|
| "conditions": "Systemic Lupus Erythematosus",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "anifrolumab",
|
| "nct_id": "NCT07430306",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-01-26",
|
| "conditions": "Systemic Lupus Erythematosus",
|
| "arm_role": "other",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "anifrolumab",
|
| "nct_id": "NCT07691970",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2032-12-31",
|
| "conditions": "Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "axitinib",
|
| "nct_id": "NCT05059522",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-12-31",
|
| "conditions": "Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "axitinib",
|
| "nct_id": "NCT06364631",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2032-05-05",
|
| "conditions": "Metastatic Kidney Cancer; Metastatic Kidney Carcinoma",
|
| "arm_role": "other",
|
| "sponsor_raw": "Gustave Roussy, Cancer Campus, Grand Paris",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "belzutifan",
|
| "nct_id": "NCT04195750",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2024-04-15",
|
| "conditions": "Carcinoma, Renal Cell",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "belzutifan",
|
| "nct_id": "NCT04586231",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-02-02",
|
| "conditions": "Carcinoma, Renal Cell",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "belzutifan",
|
| "nct_id": "NCT04736706",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-10-29",
|
| "conditions": "Carcinoma, Renal Cell",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "belzutifan",
|
| "nct_id": "NCT05239728",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-10-28",
|
| "conditions": "Carcinoma, Renal Cell",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "belzutifan",
|
| "nct_id": "NCT05899049",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-06-07",
|
| "conditions": "Carcinoma, Renal Cell",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "belzutifan",
|
| "nct_id": "NCT07227402",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2032-02-27",
|
| "conditions": "Renal Cell Carcinoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "belzutifan",
|
| "nct_id": "NCT07405164",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2034-01-14",
|
| "conditions": "Von Hippel-Lindau Disease; Malignant Neoplasms",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "belzutifan",
|
| "nct_id": "NCT07489495",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2030-11-27",
|
| "conditions": "Carcinoma, Renal Cell",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "binimetinib",
|
| "nct_id": "NCT04657991",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-01-12",
|
| "conditions": "Melanoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "binimetinib",
|
| "nct_id": "NCT05615818",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-06",
|
| "conditions": "Biliary Tract Neoplasms",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "UNICANCER",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "cagrilintide",
|
| "nct_id": "NCT05567796",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2024-10-30",
|
| "conditions": "Obesity",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novo Nordisk A/S",
|
| "company_name": "NOVO NORDISK A S",
|
| "ticker": "NVO"
|
| },
|
| {
|
| "asset": "cagrilintide",
|
| "nct_id": "NCT05669755",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-09-01",
|
| "conditions": "Cardiovascular Disease",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novo Nordisk A/S",
|
| "company_name": "NOVO NORDISK A S",
|
| "ticker": "NVO"
|
| },
|
| {
|
| "asset": "cagrilintide",
|
| "nct_id": "NCT06780449",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2028-08-28",
|
| "conditions": "Obesity",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novo Nordisk A/S",
|
| "company_name": "NOVO NORDISK A S",
|
| "ticker": "NVO"
|
| },
|
| {
|
| "asset": "cagrilintide",
|
| "nct_id": "NCT07011667",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-03-01",
|
| "conditions": "Obesity",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novo Nordisk A/S",
|
| "company_name": "NOVO NORDISK A S",
|
| "ticker": "NVO"
|
| },
|
| {
|
| "asset": "cagrilintide",
|
| "nct_id": "NCT07220642",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-05-11",
|
| "conditions": "Obesity; Overweight",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novo Nordisk A/S",
|
| "company_name": "NOVO NORDISK A S",
|
| "ticker": "NVO"
|
| },
|
| {
|
| "asset": "cagrilintide",
|
| "nct_id": "NCT07220759",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-05-12",
|
| "conditions": "Overweight; Obesity; Type 2 Diabetes",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novo Nordisk A/S",
|
| "company_name": "NOVO NORDISK A S",
|
| "ticker": "NVO"
|
| },
|
| {
|
| "asset": "cagrilintide",
|
| "nct_id": "NCT07253285",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2030-03-20",
|
| "conditions": "Overweight; Obesity",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novo Nordisk A/S",
|
| "company_name": "NOVO NORDISK A S",
|
| "ticker": "NVO"
|
| },
|
| {
|
| "asset": "cagrilintide",
|
| "nct_id": "NCT07282613",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2029-09-07",
|
| "conditions": "Diabetes Mellitus, Type 2",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novo Nordisk A/S",
|
| "company_name": "NOVO NORDISK A S",
|
| "ticker": "NVO"
|
| },
|
| {
|
| "asset": "cagrilintide",
|
| "nct_id": "NCT07564414",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-02-23",
|
| "conditions": "Obesity; Type 2 Diabetes",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novo Nordisk A/S",
|
| "company_name": "NOVO NORDISK A S",
|
| "ticker": "NVO"
|
| },
|
| {
|
| "asset": "camizestrant",
|
| "nct_id": "NCT04711252",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-08-24",
|
| "conditions": "ER-Positive HER2-Negative Breast Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "camizestrant",
|
| "nct_id": "NCT04964934",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2025-06-30",
|
| "conditions": "ER-Positive HER2-Negative Breast Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "camizestrant",
|
| "nct_id": "NCT05774951",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-04-20",
|
| "conditions": "Breast Cancer, Early Breast Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "camizestrant",
|
| "nct_id": "NCT05952557",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2030-03-04",
|
| "conditions": "Breast Cancer, Early Breast Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "camizestrant",
|
| "nct_id": "NCT06380751",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-03-30",
|
| "conditions": "Advanced Breast Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "camizestrant",
|
| "nct_id": "NCT07647328",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-02-28",
|
| "conditions": "ER-Positive HER2-Negative Breast Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "cenerimod",
|
| "nct_id": "NCT05648500",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-10-31",
|
| "conditions": "Lupus Erythematosus, Systemic",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Viatris Innovation GmbH",
|
| "company_name": "Viatris Inc",
|
| "ticker": "VTRS"
|
| },
|
| {
|
| "asset": "cenerimod",
|
| "nct_id": "NCT05672576",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-10-31",
|
| "conditions": "Lupus Erythematosus, Systemic",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Viatris Innovation GmbH",
|
| "company_name": "Viatris Inc",
|
| "ticker": "VTRS"
|
| },
|
| {
|
| "asset": "cenerimod",
|
| "nct_id": "NCT06475742",
|
| "phase": "PHASE3",
|
| "status": "ENROLLING_BY_INVITATION",
|
| "primary_completion": "2028-05",
|
| "conditions": "Lupus Erythematosus, Systemic",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Viatris Innovation GmbH",
|
| "company_name": "Viatris Inc",
|
| "ticker": "VTRS"
|
| },
|
| {
|
| "asset": "cenerimod",
|
| "nct_id": "NCT07201129",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-08",
|
| "conditions": "Nephritis, Lupus; Lupus Erythematosus, Systemic",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Viatris Innovation GmbH",
|
| "company_name": "Viatris Inc",
|
| "ticker": "VTRS"
|
| },
|
| {
|
| "asset": "cretostimogene grenadenorepvec",
|
| "nct_id": "NCT04452591",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2030-06-16",
|
| "conditions": "Non Muscle Invasive Bladder Cancer; High-grade Ta/ T1 Papillary Disease Bladder Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "CG Oncology, Inc.",
|
| "company_name": "CG Oncology, Inc.",
|
| "ticker": "CGON"
|
| },
|
| {
|
| "asset": "cretostimogene grenadenorepvec",
|
| "nct_id": "NCT06111235",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-11",
|
| "conditions": "Non Muscle Invasive Bladder Cancer; Urologic Cancer; Bladder Cancer; Urothelial Carcinoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "CG Oncology, Inc.",
|
| "company_name": "CG Oncology, Inc.",
|
| "ticker": "CGON"
|
| },
|
| {
|
| "asset": "dapagliflozin",
|
| "nct_id": "NCT05374291",
|
| "phase": "PHASE3",
|
| "status": "ENROLLING_BY_INVITATION",
|
| "primary_completion": "2027-07",
|
| "conditions": "Kidney Disease, Chronic; Renal Transplant Failure; Heart Failure; Kidney Failure; Death",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "University Medical Center Groningen",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "dapagliflozin",
|
| "nct_id": "NCT05886088",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2026-05",
|
| "conditions": "Type 2 Diabetes Mellitus",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "EMS",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "dapagliflozin",
|
| "nct_id": "NCT07082114",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-02-16",
|
| "conditions": "Type 2 Diabetes",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "dapagliflozin",
|
| "nct_id": "NCT07662044",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-07-14",
|
| "conditions": "Type 2 Diabetes Mellitus",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "dapagliflozin",
|
| "nct_id": "NCT07662109",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-07-05",
|
| "conditions": "Type 2 Diabetes Mellitus",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "darolutamide",
|
| "nct_id": "NCT03903835",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-12",
|
| "conditions": "Metastatic Castration-resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Karolinska Institutet",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "darolutamide",
|
| "nct_id": "NCT04136353",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2028-01-31",
|
| "conditions": "Prostate Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "University of Sydney",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "darolutamide",
|
| "nct_id": "NCT04464226",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2028-06-26",
|
| "conditions": "Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Bayer",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "darolutamide",
|
| "nct_id": "NCT04916613",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-03",
|
| "conditions": "Prostate Cancer Metastatic",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "UNICANCER",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "darolutamide",
|
| "nct_id": "NCT05116475",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-02",
|
| "conditions": "Prostate Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "darolutamide",
|
| "nct_id": "NCT05794906",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-07-30",
|
| "conditions": "Biochemically Recurrent Prostate Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Bayer",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "darolutamide",
|
| "nct_id": "NCT06120491",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-09-30",
|
| "conditions": "Metastatic Castration-Sensitive Prostate Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "darolutamide",
|
| "nct_id": "NCT06276465",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-10-15",
|
| "conditions": "Prostatic Cancer, Castration-Resistant",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "UNICANCER",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "darolutamide",
|
| "nct_id": "NCT06282588",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2030-07-31",
|
| "conditions": "Prostate Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Cancer Research Antwerp",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "darolutamide",
|
| "nct_id": "NCT06625970",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2033-10",
|
| "conditions": "High Risk Prostate Carcinoma; Prostate Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "UNICANCER",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "darolutamide",
|
| "nct_id": "NCT07611110",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-02-13",
|
| "conditions": "Metastatic Castration-resistant Prostate Cancer",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "darolutamide",
|
| "nct_id": "NCT07711002",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2031-06-17",
|
| "conditions": "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "darovasertib",
|
| "nct_id": "NCT05987332",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-01-15",
|
| "conditions": "Metastatic Uveal Melanoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "IDEAYA Biosciences",
|
| "company_name": "IDEAYA Biosciences, Inc.",
|
| "ticker": "IDYA"
|
| },
|
| {
|
| "asset": "darovasertib",
|
| "nct_id": "NCT07015190",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2030-10",
|
| "conditions": "Uveal Melanoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "IDEAYA Biosciences",
|
| "company_name": "IDEAYA Biosciences, Inc.",
|
| "ticker": "IDYA"
|
| },
|
| {
|
| "asset": "datopotamab deruxtecan",
|
| "nct_id": "NCT04656652",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2024-05-10",
|
| "conditions": "Non-small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Daiichi Sankyo",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "datopotamab deruxtecan",
|
| "nct_id": "NCT05104866",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2024-07-24",
|
| "conditions": "Breast Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "datopotamab deruxtecan",
|
| "nct_id": "NCT05215340",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2030-03-04",
|
| "conditions": "Metastatic Non Small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Daiichi Sankyo",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "datopotamab deruxtecan",
|
| "nct_id": "NCT05374512",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2025-08-25",
|
| "conditions": "Breast Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "datopotamab deruxtecan",
|
| "nct_id": "NCT05555732",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2029-05-11",
|
| "conditions": "Metastatic Non Small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Daiichi Sankyo",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "datopotamab deruxtecan",
|
| "nct_id": "NCT05629585",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-09-20",
|
| "conditions": "Breast Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "datopotamab deruxtecan",
|
| "nct_id": "NCT05687266",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-11-01",
|
| "conditions": "NSCLC",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "datopotamab deruxtecan",
|
| "nct_id": "NCT06103864",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-07-28",
|
| "conditions": "Breast Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "datopotamab deruxtecan",
|
| "nct_id": "NCT06112379",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2028-11-20",
|
| "conditions": "Breast Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "datopotamab deruxtecan",
|
| "nct_id": "NCT06350097",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-03-21",
|
| "conditions": "Non-small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "datopotamab deruxtecan",
|
| "nct_id": "NCT06357533",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-12-28",
|
| "conditions": "Non-Small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "datopotamab deruxtecan",
|
| "nct_id": "NCT06417814",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-09-30",
|
| "conditions": "Metastatic Non-small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "datopotamab deruxtecan",
|
| "nct_id": "NCT06564844",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-06-30",
|
| "conditions": "Non-small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "datopotamab deruxtecan",
|
| "nct_id": "NCT07129993",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-06-01",
|
| "conditions": "Urothelial Cancer; Bladder Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Daiichi Sankyo",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "datopotamab deruxtecan",
|
| "nct_id": "NCT07205822",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-02-02",
|
| "conditions": "Breast Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "datopotamab deruxtecan",
|
| "nct_id": "NCT07291037",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-01-29",
|
| "conditions": "Non-small Cell Lung Cancer (NSCLC)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "daunorubicin",
|
| "nct_id": "NCT03117751",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-09-30",
|
| "conditions": "Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "St. Jude Children's Research Hospital",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "daunorubicin",
|
| "nct_id": "NCT03897127",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-06",
|
| "conditions": "Acute Myeloid Leukemia",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "University of Ulm",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "daunorubicin",
|
| "nct_id": "NCT05726110",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2024-12-10",
|
| "conditions": "Relapsed or Refractory Acute Myeloid Leukemia",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Shanxi Bethune Hospital",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "daunorubicin",
|
| "nct_id": "NCT07007312",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2031-11",
|
| "conditions": "Acute Myeloid Leukemia (AML)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Kura Oncology, Inc.",
|
| "company_name": "Kura Oncology, Inc.",
|
| "ticker": "KURA"
|
| },
|
| {
|
| "asset": "daunorubicin",
|
| "nct_id": "NCT07255872",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2027-12",
|
| "conditions": "Acute Myeloid Leukemia",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Sichuan Baili Pharmaceutical Co., Ltd.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "deucravacitinib",
|
| "nct_id": "NCT04036435",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-07-25",
|
| "conditions": "Psoriasis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Bristol-Myers Squibb",
|
| "company_name": "BRISTOL MYERS SQUIBB CO",
|
| "ticker": "BMY"
|
| },
|
| {
|
| "asset": "deucravacitinib",
|
| "nct_id": "NCT04772079",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-01-01",
|
| "conditions": "Plaque Psoriasis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Bristol-Myers Squibb",
|
| "company_name": "BRISTOL MYERS SQUIBB CO",
|
| "ticker": "BMY"
|
| },
|
| {
|
| "asset": "deucravacitinib",
|
| "nct_id": "NCT04908189",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2024-02-06",
|
| "conditions": "Psoriatic Arthritis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Bristol-Myers Squibb",
|
| "company_name": "BRISTOL MYERS SQUIBB CO",
|
| "ticker": "BMY"
|
| },
|
| {
|
| "asset": "deucravacitinib",
|
| "nct_id": "NCT04908202",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2024-09-05",
|
| "conditions": "Psoriatic Arthritis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Bristol-Myers Squibb",
|
| "company_name": "BRISTOL MYERS SQUIBB CO",
|
| "ticker": "BMY"
|
| },
|
| {
|
| "asset": "deucravacitinib",
|
| "nct_id": "NCT05617677",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-10-19",
|
| "conditions": "Systemic Lupus Erythematosus",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Bristol-Myers Squibb",
|
| "company_name": "BRISTOL MYERS SQUIBB CO",
|
| "ticker": "BMY"
|
| },
|
| {
|
| "asset": "deucravacitinib",
|
| "nct_id": "NCT05620407",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-10-19",
|
| "conditions": "Systemic Lupus Erythematosus",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Bristol-Myers Squibb",
|
| "company_name": "BRISTOL MYERS SQUIBB CO",
|
| "ticker": "BMY"
|
| },
|
| {
|
| "asset": "deucravacitinib",
|
| "nct_id": "NCT06143878",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2024-09-17",
|
| "conditions": "Plaque Psoriasis",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Janssen Research & Development, LLC",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "deucravacitinib",
|
| "nct_id": "NCT06220604",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2024-11-15",
|
| "conditions": "Plaque Psoriasis",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Janssen Research & Development, LLC",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "deucravacitinib",
|
| "nct_id": "NCT06869551",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2030-03-06",
|
| "conditions": "Juvenile Psoriatic Arthritis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Bristol-Myers Squibb",
|
| "company_name": "BRISTOL MYERS SQUIBB CO",
|
| "ticker": "BMY"
|
| },
|
| {
|
| "asset": "deucravacitinib",
|
| "nct_id": "NCT06979453",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-10-12",
|
| "conditions": "Plaque Psoriasis",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Bristol-Myers Squibb",
|
| "company_name": "BRISTOL MYERS SQUIBB CO",
|
| "ticker": "BMY"
|
| },
|
| {
|
| "asset": "deucravacitinib",
|
| "nct_id": "NCT07116967",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2031-01-16",
|
| "conditions": "Plaque Psoriasis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Bristol-Myers Squibb",
|
| "company_name": "BRISTOL MYERS SQUIBB CO",
|
| "ticker": "BMY"
|
| },
|
| {
|
| "asset": "deucravacitinib",
|
| "nct_id": "NCT07326813",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-07-12",
|
| "conditions": "Plaque Psoriasis",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "InventisBio Co., Ltd",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "deucrictibant",
|
| "nct_id": "NCT05396105",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "ENROLLING_BY_INVITATION",
|
| "primary_completion": "2027-06",
|
| "conditions": "Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II; Hereditary Angioedema Types I and II; Hereditary Angioedema Attack; Hereditary Angioedema With C1 Esterase Inhibitor Deficiency; Hereditary Angioedema - Type 1; Hereditary Angioedema - Type 2; Hereditary Angioedema - Type 3; C1 Esterase Inhibitor [C1-INH] Deficiency; C1 Esterase Inhibitor Deficiency; C1 Esterase Inhibitor, Deficiency of; C1 Inhibitor Deficiency; Hereditary Angioedema Type III; Hereditary Angioedema (HAE); Hereditary Angioedema Type I and II; HAE With Normal C1 Esterase Inhibitor",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pharvaris Netherlands B.V.",
|
| "company_name": "Pharvaris N.V.",
|
| "ticker": "PHVS"
|
| },
|
| {
|
| "asset": "deucrictibant",
|
| "nct_id": "NCT05396105",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "ENROLLING_BY_INVITATION",
|
| "primary_completion": "2027-06",
|
| "conditions": "Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II; Hereditary Angioedema Types I and II; Hereditary Angioedema Attack; Hereditary Angioedema With C1 Esterase Inhibitor Deficiency; Hereditary Angioedema - Type 1; Hereditary Angioedema - Type 2; Hereditary Angioedema - Type 3; C1 Esterase Inhibitor [C1-INH] Deficiency; C1 Esterase Inhibitor Deficiency; C1 Esterase Inhibitor, Deficiency of; C1 Inhibitor Deficiency; Hereditary Angioedema Type III; Hereditary Angioedema (HAE); Hereditary Angioedema Type I and II; HAE With Normal C1 Esterase Inhibitor",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pharvaris Netherlands B.V.",
|
| "company_name": "Pharvaris N.V.",
|
| "ticker": "PHVS"
|
| },
|
| {
|
| "asset": "deucrictibant",
|
| "nct_id": "NCT05396105",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "ENROLLING_BY_INVITATION",
|
| "primary_completion": "2027-06",
|
| "conditions": "Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II; Hereditary Angioedema Types I and II; Hereditary Angioedema Attack; Hereditary Angioedema With C1 Esterase Inhibitor Deficiency; Hereditary Angioedema - Type 1; Hereditary Angioedema - Type 2; Hereditary Angioedema - Type 3; C1 Esterase Inhibitor [C1-INH] Deficiency; C1 Esterase Inhibitor Deficiency; C1 Esterase Inhibitor, Deficiency of; C1 Inhibitor Deficiency; Hereditary Angioedema Type III; Hereditary Angioedema (HAE); Hereditary Angioedema Type I and II; HAE With Normal C1 Esterase Inhibitor",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pharvaris Netherlands B.V.",
|
| "company_name": "Pharvaris N.V.",
|
| "ticker": "PHVS"
|
| },
|
| {
|
| "asset": "deucrictibant",
|
| "nct_id": "NCT05396105",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "ENROLLING_BY_INVITATION",
|
| "primary_completion": "2027-06",
|
| "conditions": "Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II; Hereditary Angioedema Types I and II; Hereditary Angioedema Attack; Hereditary Angioedema With C1 Esterase Inhibitor Deficiency; Hereditary Angioedema - Type 1; Hereditary Angioedema - Type 2; Hereditary Angioedema - Type 3; C1 Esterase Inhibitor [C1-INH] Deficiency; C1 Esterase Inhibitor Deficiency; C1 Esterase Inhibitor, Deficiency of; C1 Inhibitor Deficiency; Hereditary Angioedema Type III; Hereditary Angioedema (HAE); Hereditary Angioedema Type I and II; HAE With Normal C1 Esterase Inhibitor",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pharvaris Netherlands B.V.",
|
| "company_name": "Pharvaris N.V.",
|
| "ticker": "PHVS"
|
| },
|
| {
|
| "asset": "deucrictibant",
|
| "nct_id": "NCT06669754",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-08",
|
| "conditions": "Hereditary Angioedema (HAE)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pharvaris Netherlands B.V.",
|
| "company_name": "Pharvaris N.V.",
|
| "ticker": "PHVS"
|
| },
|
| {
|
| "asset": "deucrictibant",
|
| "nct_id": "NCT06679881",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-12",
|
| "conditions": "Hereditary Angioedema (HAE)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pharvaris Netherlands B.V.",
|
| "company_name": "Pharvaris N.V.",
|
| "ticker": "PHVS"
|
| },
|
| {
|
| "asset": "deucrictibant",
|
| "nct_id": "NCT07266805",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-06",
|
| "conditions": "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pharvaris Netherlands B.V.",
|
| "company_name": "Pharvaris N.V.",
|
| "ticker": "PHVS"
|
| },
|
| {
|
| "asset": "deucrictibant",
|
| "nct_id": "NCT07266805",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-06",
|
| "conditions": "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pharvaris Netherlands B.V.",
|
| "company_name": "Pharvaris N.V.",
|
| "ticker": "PHVS"
|
| },
|
| {
|
| "asset": "deucrictibant",
|
| "nct_id": "NCT07266805",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-06",
|
| "conditions": "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pharvaris Netherlands B.V.",
|
| "company_name": "Pharvaris N.V.",
|
| "ticker": "PHVS"
|
| },
|
| {
|
| "asset": "deucrictibant",
|
| "nct_id": "NCT07266805",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-06",
|
| "conditions": "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pharvaris Netherlands B.V.",
|
| "company_name": "Pharvaris N.V.",
|
| "ticker": "PHVS"
|
| },
|
| {
|
| "asset": "deucrictibant",
|
| "nct_id": "NCT07266805",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-06",
|
| "conditions": "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pharvaris Netherlands B.V.",
|
| "company_name": "Pharvaris N.V.",
|
| "ticker": "PHVS"
|
| },
|
| {
|
| "asset": "deucrictibant",
|
| "nct_id": "NCT07266805",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-06",
|
| "conditions": "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pharvaris Netherlands B.V.",
|
| "company_name": "Pharvaris N.V.",
|
| "ticker": "PHVS"
|
| },
|
| {
|
| "asset": "deucrictibant",
|
| "nct_id": "NCT07266805",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-06",
|
| "conditions": "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pharvaris Netherlands B.V.",
|
| "company_name": "Pharvaris N.V.",
|
| "ticker": "PHVS"
|
| },
|
| {
|
| "asset": "deucrictibant",
|
| "nct_id": "NCT07266805",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-06",
|
| "conditions": "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pharvaris Netherlands B.V.",
|
| "company_name": "Pharvaris N.V.",
|
| "ticker": "PHVS"
|
| },
|
| {
|
| "asset": "deucrictibant",
|
| "nct_id": "NCT07266805",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-06",
|
| "conditions": "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pharvaris Netherlands B.V.",
|
| "company_name": "Pharvaris N.V.",
|
| "ticker": "PHVS"
|
| },
|
| {
|
| "asset": "deuruxolitinib",
|
| "nct_id": "NCT03898479",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-05",
|
| "conditions": "Alopecia Areata",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Sun Pharmaceutical Industries, Inc.",
|
| "company_name": "TEVA PHARMACEUTICAL INDUSTRIES LTD",
|
| "ticker": "TEVA"
|
| },
|
| {
|
| "asset": "deuruxolitinib",
|
| "nct_id": "NCT07133308",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-05",
|
| "conditions": "Alopecia Areata",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Sun Pharmaceutical Industries, Inc.",
|
| "company_name": "TEVA PHARMACEUTICAL INDUSTRIES LTD",
|
| "ticker": "TEVA"
|
| },
|
| {
|
| "asset": "deuruxolitinib",
|
| "nct_id": "NCT07617597",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-02",
|
| "conditions": "Alopecia Areata",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Sun Pharma Japan Limited",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "disitamab vedotin",
|
| "nct_id": "NCT05302284",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-12-31",
|
| "conditions": "Urothelial Carcinoma; HER2-expressing",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "RemeGen Co., Ltd.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "disitamab vedotin",
|
| "nct_id": "NCT05911295",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-01-29",
|
| "conditions": "Urothelial Carcinoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Seagen, a wholly owned subsidiary of Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "disitamab vedotin",
|
| "nct_id": "NCT05980481",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2025-07-10",
|
| "conditions": "Gastric Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "RemeGen Co., Ltd.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "disitamab vedotin",
|
| "nct_id": "NCT05980481",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2025-07-10",
|
| "conditions": "Gastric Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "RemeGen Co., Ltd.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "disitamab vedotin",
|
| "nct_id": "NCT06221748",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-12",
|
| "conditions": "Gastric Cancer; Gastroesophageal Junction Adenocarcinoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "RemeGen Co., Ltd.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "disitamab vedotin",
|
| "nct_id": "NCT07315750",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-06-30",
|
| "conditions": "Gastric Carcinoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "RemeGen Co., Ltd.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "donidalorsen",
|
| "nct_id": "NCT05392114",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-12",
|
| "conditions": "Hereditary Angioedema",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Ionis Pharmaceuticals, Inc.",
|
| "company_name": "IONIS PHARMACEUTICALS INC",
|
| "ticker": "IONS"
|
| },
|
| {
|
| "asset": "donidalorsen",
|
| "nct_id": "NCT07298447",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-06",
|
| "conditions": "Hereditary Angioedema (HAE)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Ionis Pharmaceuticals, Inc.",
|
| "company_name": "IONIS PHARMACEUTICALS INC",
|
| "ticker": "IONS"
|
| },
|
| {
|
| "asset": "efgartigimod",
|
| "nct_id": "NCT04833894",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-03",
|
| "conditions": "Generalized Myasthenia Gravis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "argenx",
|
| "company_name": "ARGENX SE",
|
| "ticker": "ARGX"
|
| },
|
| {
|
| "asset": "efgartigimod",
|
| "nct_id": "NCT06298552",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2025-06-30",
|
| "conditions": "Generalized Myasthenia Gravis; gMG; Myasthenia Gravis, Generalized; Myasthenia Gravis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "argenx",
|
| "company_name": "ARGENX SE",
|
| "ticker": "ARGX"
|
| },
|
| {
|
| "asset": "efgartigimod",
|
| "nct_id": "NCT07217587",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-09-28",
|
| "conditions": "Myasthenia Gravis",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Janssen Research & Development, LLC",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "eftilagimod alfa",
|
| "nct_id": "NCT06726265",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-06",
|
| "conditions": "Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Immutep S.A.S.",
|
| "company_name": "IMMUTEP Ltd",
|
| "ticker": "IMMP"
|
| },
|
| {
|
| "asset": "eftilagimod alpha",
|
| "nct_id": "NCT05747794",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-10-31",
|
| "conditions": "Breast Carcinoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Immutep S.A.S.",
|
| "company_name": "IMMUTEP Ltd",
|
| "ticker": "IMMP"
|
| },
|
| {
|
| "asset": "elranatamab",
|
| "nct_id": "NCT05020236",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-04-27",
|
| "conditions": "Multiple Myeloma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "elranatamab",
|
| "nct_id": "NCT05317416",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-08-04",
|
| "conditions": "Multiple Myeloma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "elranatamab",
|
| "nct_id": "NCT05317416",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-08-04",
|
| "conditions": "Multiple Myeloma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "elranatamab",
|
| "nct_id": "NCT05317416",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-08-04",
|
| "conditions": "Multiple Myeloma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "elranatamab",
|
| "nct_id": "NCT05317416",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-08-04",
|
| "conditions": "Multiple Myeloma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "elranatamab",
|
| "nct_id": "NCT05623020",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2030-10-18",
|
| "conditions": "Multiple Myeloma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "elranatamab",
|
| "nct_id": "NCT06152575",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-08-30",
|
| "conditions": "Multiple Myeloma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "elranatamab",
|
| "nct_id": "NCT06918002",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2036-05",
|
| "conditions": "Multiple Myeloma, Newly Diagnosed",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Intergroupe Francophone du Myelome",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "elranatamab",
|
| "nct_id": "NCT07647432",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2029-12-01",
|
| "conditions": "Plasmablastic Lymphoma; Hiv; Consolidation",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "University of Illinois at Chicago",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "encorafenib",
|
| "nct_id": "NCT04607421",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2025-03-01",
|
| "conditions": "Neoplasms",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "encorafenib",
|
| "nct_id": "NCT04657991",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-01-12",
|
| "conditions": "Melanoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "encorafenib",
|
| "nct_id": "NCT05615818",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-06",
|
| "conditions": "Biliary Tract Neoplasms",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "UNICANCER",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "enlicitide decanoate",
|
| "nct_id": "NCT06008756",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2029-11-29",
|
| "conditions": "Arteriosclerosis; Hypercholesterolaemia",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "enlicitide decanoate",
|
| "nct_id": "NCT06492291",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2028-10-13",
|
| "conditions": "Hypercholesterolemia",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "enlicitide decanoate",
|
| "nct_id": "NCT07058077",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2033-12-04",
|
| "conditions": "Heterozygous Familial Hypercholesterolemia (HeFH)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "enlicitide decanoate",
|
| "nct_id": "NCT07216482",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-12-02",
|
| "conditions": "Hyperlipidemia",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "epcoritamab",
|
| "nct_id": "NCT04628494",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2025-10-13",
|
| "conditions": "Diffuse Large B-cell Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Genmab",
|
| "company_name": "GENMAB A/S",
|
| "ticker": "GMAB"
|
| },
|
| {
|
| "asset": "epcoritamab",
|
| "nct_id": "NCT05409066",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2029-12",
|
| "conditions": "Follicular Lymphoma (FL)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Genmab",
|
| "company_name": "GENMAB A/S",
|
| "ticker": "GMAB"
|
| },
|
| {
|
| "asset": "epcoritamab",
|
| "nct_id": "NCT05578976",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-06",
|
| "conditions": "Diffuse Large B-Cell Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Genmab",
|
| "company_name": "GENMAB A/S",
|
| "ticker": "GMAB"
|
| },
|
| {
|
| "asset": "epcoritamab",
|
| "nct_id": "NCT06191744",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2037-11",
|
| "conditions": "Follicular Lymphoma (FL)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Genmab",
|
| "company_name": "GENMAB A/S",
|
| "ticker": "GMAB"
|
| },
|
| {
|
| "asset": "epcoritamab",
|
| "nct_id": "NCT06508658",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2028-03",
|
| "conditions": "Diffuse Large B-Cell Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Genmab",
|
| "company_name": "GENMAB A/S",
|
| "ticker": "GMAB"
|
| },
|
| {
|
| "asset": "epcoritamab",
|
| "nct_id": "NCT07226752",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2025-10-13",
|
| "conditions": "Diffuse Large B-Cell Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Genmab",
|
| "company_name": "GENMAB A/S",
|
| "ticker": "GMAB"
|
| },
|
| {
|
| "asset": "erwinia asparaginase",
|
| "nct_id": "NCT03020030",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-11-30",
|
| "conditions": "Acute Lymphoblastic Leukemia, Pediatric",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Dana-Farber Cancer Institute",
|
| "company_name": "DANA Inc",
|
| "ticker": "DAN"
|
| },
|
| {
|
| "asset": "erwinia asparaginase",
|
| "nct_id": "NCT03117751",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-09-30",
|
| "conditions": "Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "St. Jude Children's Research Hospital",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "fianlimab",
|
| "nct_id": "NCT05352672",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-03-12",
|
| "conditions": "Melanoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Regeneron Pharmaceuticals",
|
| "company_name": "REGENERON PHARMACEUTICALS, INC.",
|
| "ticker": "REGN"
|
| },
|
| {
|
| "asset": "fianlimab",
|
| "nct_id": "NCT05608291",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-07-27",
|
| "conditions": "Melanoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Regeneron Pharmaceuticals",
|
| "company_name": "REGENERON PHARMACEUTICALS, INC.",
|
| "ticker": "REGN"
|
| },
|
| {
|
| "asset": "fianlimab",
|
| "nct_id": "NCT05785767",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-09-28",
|
| "conditions": "Advanced Non-Small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Regeneron Pharmaceuticals",
|
| "company_name": "REGENERON PHARMACEUTICALS, INC.",
|
| "ticker": "REGN"
|
| },
|
| {
|
| "asset": "fianlimab",
|
| "nct_id": "NCT05800015",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2030-01-16",
|
| "conditions": "Non-small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Regeneron Pharmaceuticals",
|
| "company_name": "REGENERON PHARMACEUTICALS, INC.",
|
| "ticker": "REGN"
|
| },
|
| {
|
| "asset": "fianlimab",
|
| "nct_id": "NCT06246916",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-03-22",
|
| "conditions": "Melanoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Regeneron Pharmaceuticals",
|
| "company_name": "REGENERON PHARMACEUTICALS, INC.",
|
| "ticker": "REGN"
|
| },
|
| {
|
| "asset": "golcadomide",
|
| "nct_id": "NCT06356129",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-08-09",
|
| "conditions": "Large B-cell Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Celgene",
|
| "company_name": "BRISTOL MYERS SQUIBB CO",
|
| "ticker": "BMY"
|
| },
|
| {
|
| "asset": "golcadomide",
|
| "nct_id": "NCT06911502",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-04-24",
|
| "conditions": "Follicular Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Celgene",
|
| "company_name": "BRISTOL MYERS SQUIBB CO",
|
| "ticker": "BMY"
|
| },
|
| {
|
| "asset": "ianalumab",
|
| "nct_id": "NCT05624749",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-04-12",
|
| "conditions": "Systemic Lupus Erythematosus",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novartis Pharmaceuticals",
|
| "company_name": "NOVARTIS AG",
|
| "ticker": "NVS"
|
| },
|
| {
|
| "asset": "ianalumab",
|
| "nct_id": "NCT05639114",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-03-24",
|
| "conditions": "Systemic Lupus Erythematosus",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novartis Pharmaceuticals",
|
| "company_name": "NOVARTIS AG",
|
| "ticker": "NVS"
|
| },
|
| {
|
| "asset": "ianalumab",
|
| "nct_id": "NCT06133972",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2030-04-08",
|
| "conditions": "Systemic Lupus Erythematosus",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novartis Pharmaceuticals",
|
| "company_name": "NOVARTIS AG",
|
| "ticker": "NVS"
|
| },
|
| {
|
| "asset": "ianalumab",
|
| "nct_id": "NCT06711887",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2035-08-01",
|
| "conditions": "Lupus Nephritis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novartis Pharmaceuticals",
|
| "company_name": "NOVARTIS AG",
|
| "ticker": "NVS"
|
| },
|
| {
|
| "asset": "ibrutinib",
|
| "nct_id": "NCT01804686",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-12-31",
|
| "conditions": "Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Diffuse Large B-cell Lymphoma; Waldenstrom Macroglobulinemia; Chronic Graft Versus Host Disease",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Janssen Research & Development, LLC",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "ibrutinib",
|
| "nct_id": "NCT02477696",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2020-09-15",
|
| "conditions": "Chronic Lymphocytic Leukemia",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Acerta Pharma BV",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "ibrutinib",
|
| "nct_id": "NCT03462719",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2021-02-26",
|
| "conditions": "Leukemia, Lymphocytic, Chronic, B-Cell",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Janssen Research & Development, LLC",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "ibrutinib",
|
| "nct_id": "NCT03462719",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2021-02-26",
|
| "conditions": "Leukemia, Lymphocytic, Chronic, B-Cell",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Janssen Research & Development, LLC",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "ibrutinib",
|
| "nct_id": "NCT04212013",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-03-18",
|
| "conditions": "Marginal Zone Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Memorial Sloan Kettering Cancer Center",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "ibrutinib",
|
| "nct_id": "NCT04608318",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-09",
|
| "conditions": "Chronic Lymphoid Leukemia",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "German CLL Study Group",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "ibrutinib",
|
| "nct_id": "NCT04662255",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-01",
|
| "conditions": "Lymphoma, Mantle-Cell",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Loxo Oncology, Inc.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "ibrutinib",
|
| "nct_id": "NCT05254743",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-10",
|
| "conditions": "Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic; Leukemia, B-cell; Small Lymphocytic Lymphoma",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Loxo Oncology, Inc.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "ibrutinib",
|
| "nct_id": "NCT06136559",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2032-09-07",
|
| "conditions": "Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "ibrutinib",
|
| "nct_id": "NCT07377578",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2031-05-30",
|
| "conditions": "Mantle Cell Lymphoma",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Guangzhou Lupeng Pharmaceutical Company LTD.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "ifinatamab deruxtecan",
|
| "nct_id": "NCT06203210",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-04-30",
|
| "conditions": "Small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Daiichi Sankyo",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "ifinatamab deruxtecan",
|
| "nct_id": "NCT06644781",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-06-01",
|
| "conditions": "Esophageal Squamous Cell Carcinoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Daiichi Sankyo",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "ifinatamab deruxtecan",
|
| "nct_id": "NCT06925737",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-06-26",
|
| "conditions": "Prostate Cancer; Prostatic Neoplasms",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "inclisiran",
|
| "nct_id": "NCT03705234",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-10",
|
| "conditions": "Atherosclerotic Cardiovascular Disease",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "University of Oxford",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "inclisiran",
|
| "nct_id": "NCT04765657",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2022-06-09",
|
| "conditions": "Hypercholesterolemia",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novartis Pharmaceuticals",
|
| "company_name": "NOVARTIS AG",
|
| "ticker": "NVS"
|
| },
|
| {
|
| "asset": "inclisiran",
|
| "nct_id": "NCT05030428",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-10-13",
|
| "conditions": "Atherosclerotic Cardiovascular Disease",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novartis Pharmaceuticals",
|
| "company_name": "NOVARTIS AG",
|
| "ticker": "NVS"
|
| },
|
| {
|
| "asset": "inclisiran",
|
| "nct_id": "NCT05360446",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-10-26",
|
| "conditions": "Coronary Artery Disease",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novartis Pharmaceuticals",
|
| "company_name": "NOVARTIS AG",
|
| "ticker": "NVS"
|
| },
|
| {
|
| "asset": "inclisiran",
|
| "nct_id": "NCT05682378",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2032-03-25",
|
| "conditions": "Heterozygous or Homozygous Familial Hypercholesterolemia",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novartis Pharmaceuticals",
|
| "company_name": "NOVARTIS AG",
|
| "ticker": "NVS"
|
| },
|
| {
|
| "asset": "inclisiran",
|
| "nct_id": "NCT06597006",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-03-23",
|
| "conditions": "Familial Hypercholesterolemia - Homozygous",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novartis Pharmaceuticals",
|
| "company_name": "NOVARTIS AG",
|
| "ticker": "NVS"
|
| },
|
| {
|
| "asset": "inclisiran",
|
| "nct_id": "NCT06597019",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-03-21",
|
| "conditions": "Familial Hypercholesterolemia - Heterozygous",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novartis Pharmaceuticals",
|
| "company_name": "NOVARTIS AG",
|
| "ticker": "NVS"
|
| },
|
| {
|
| "asset": "inclisiran",
|
| "nct_id": "NCT06813911",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-02-03",
|
| "conditions": "Atherosclerotic Cardiovascular Disease (ASCVD)",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Novartis Pharmaceuticals",
|
| "company_name": "NOVARTIS AG",
|
| "ticker": "NVS"
|
| },
|
| {
|
| "asset": "inclisiran",
|
| "nct_id": "NCT07102628",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-02-11",
|
| "conditions": "Acute Coronary Syndrome",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novartis Pharmaceuticals",
|
| "company_name": "NOVARTIS AG",
|
| "ticker": "NVS"
|
| },
|
| {
|
| "asset": "iptacopan",
|
| "nct_id": "NCT06517758",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-04-30",
|
| "conditions": "Generalized Myasthenia Gravis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novartis Pharmaceuticals",
|
| "company_name": "NOVARTIS AG",
|
| "ticker": "NVS"
|
| },
|
| {
|
| "asset": "ivonescimab",
|
| "nct_id": "NCT05184712",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2023-03-10",
|
| "conditions": "Non-Squamous Non-small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Akeso",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "ivonescimab",
|
| "nct_id": "NCT05499390",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2024-01-29",
|
| "conditions": "Advanced Non-small-cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Akeso",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "ivonescimab",
|
| "nct_id": "NCT05899608",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-12-31",
|
| "conditions": "Non-Small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Summit Therapeutics",
|
| "company_name": "Summit Therapeutics Inc.",
|
| "ticker": "SMMT"
|
| },
|
| {
|
| "asset": "ivonescimab",
|
| "nct_id": "NCT06396065",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2025-04-12",
|
| "conditions": "Non-Squamous Non-small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Summit Therapeutics",
|
| "company_name": "Summit Therapeutics Inc.",
|
| "ticker": "SMMT"
|
| },
|
| {
|
| "asset": "ivonescimab",
|
| "nct_id": "NCT06767514",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-04",
|
| "conditions": "Non-Small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Summit Therapeutics",
|
| "company_name": "Summit Therapeutics Inc.",
|
| "ticker": "SMMT"
|
| },
|
| {
|
| "asset": "ivonescimab",
|
| "nct_id": "NCT06767527",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-12",
|
| "conditions": "Triple-Negative Breast Cancer (TNBC)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Akeso",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "ivonescimab",
|
| "nct_id": "NCT06951503",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-01-13",
|
| "conditions": "Colorectal Adenocarcinoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Akeso",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "ivonescimab",
|
| "nct_id": "NCT07010263",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-12-31",
|
| "conditions": "Small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Akeso",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "ivonescimab",
|
| "nct_id": "NCT07228832",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-05-31",
|
| "conditions": "Metastatic Colorectal Cancer (CRC)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Summit Therapeutics",
|
| "company_name": "Summit Therapeutics Inc.",
|
| "ticker": "SMMT"
|
| },
|
| {
|
| "asset": "laroprovstat",
|
| "nct_id": "NCT06834932",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-02-22",
|
| "conditions": "Dyslipidaemia",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "laroprovstat",
|
| "nct_id": "NCT07000123",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-01-11",
|
| "conditions": "Cardiovascular Disease",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "laroprovstat",
|
| "nct_id": "NCT07000136",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-01-04",
|
| "conditions": "Heterozygous Familial Hypercholesterolaemia",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "laroprovstat",
|
| "nct_id": "NCT07000357",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-10-26",
|
| "conditions": "Cardiovascular Disease",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "laroprovstat",
|
| "nct_id": "NCT07619131",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2027-07-30",
|
| "conditions": "Hypercholesterolaemia",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "lebrikizumab",
|
| "nct_id": "NCT05559359",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-01-14",
|
| "conditions": "Atopic Dermatitis; Eczema",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "lebrikizumab",
|
| "nct_id": "NCT05735483",
|
| "phase": "PHASE3",
|
| "status": "ENROLLING_BY_INVITATION",
|
| "primary_completion": "2027-12",
|
| "conditions": "Atopic Dermatitis; Eczema",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "lebrikizumab",
|
| "nct_id": "NCT06280716",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2025-09-25",
|
| "conditions": "Atopic Dermatitis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "lebrikizumab",
|
| "nct_id": "NCT06526182",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-04-25",
|
| "conditions": "Dermatitis, Atopic; Eczema",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Almirall, S.A.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "lebrikizumab",
|
| "nct_id": "NCT07542483",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2028-08",
|
| "conditions": "Nummular Eczema",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Almirall, S.A.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "lerotinib",
|
| "nct_id": "NCT04415853",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-08",
|
| "conditions": "Esophageal Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Sunshine Lake Pharma Co., Ltd.",
|
| "company_name": "Sunshine Biopharma Inc.",
|
| "ticker": "SBFM"
|
| },
|
| {
|
| "asset": "lisaftoclax",
|
| "nct_id": "NCT06319456",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-08",
|
| "conditions": "CLL/SLL",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Ascentage Pharma Group Inc.",
|
| "company_name": "ASCENTAGE PHARMA GROUP INTERNATIONAL",
|
| "ticker": "AAPG"
|
| },
|
| {
|
| "asset": "lisaftoclax",
|
| "nct_id": "NCT06389292",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-05-25",
|
| "conditions": "Acute Myeloid Leukemia",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Ascentage Pharma Group Inc.",
|
| "company_name": "ASCENTAGE PHARMA GROUP INTERNATIONAL",
|
| "ticker": "AAPG"
|
| },
|
| {
|
| "asset": "litifilimab",
|
| "nct_id": "NCT04895241",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-09-30",
|
| "conditions": "Lupus Erythematosus, Systemic",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Biogen",
|
| "company_name": "BIOGEN INC.",
|
| "ticker": "BIIB"
|
| },
|
| {
|
| "asset": "litifilimab",
|
| "nct_id": "NCT04961567",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-09-27",
|
| "conditions": "Lupus Erythematosus, Systemic",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Biogen",
|
| "company_name": "BIOGEN INC.",
|
| "ticker": "BIIB"
|
| },
|
| {
|
| "asset": "litifilimab",
|
| "nct_id": "NCT05352919",
|
| "phase": "PHASE3",
|
| "status": "ENROLLING_BY_INVITATION",
|
| "primary_completion": "2030-03-29",
|
| "conditions": "Systemic Lupus Erythematosus (SLE)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Biogen",
|
| "company_name": "BIOGEN INC.",
|
| "ticker": "BIIB"
|
| },
|
| {
|
| "asset": "litifilimab",
|
| "nct_id": "NCT05531565",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-10-20",
|
| "conditions": "Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Biogen",
|
| "company_name": "BIOGEN INC.",
|
| "ticker": "BIIB"
|
| },
|
| {
|
| "asset": "litifilimab",
|
| "nct_id": "NCT06044337",
|
| "phase": "PHASE3",
|
| "status": "ENROLLING_BY_INVITATION",
|
| "primary_completion": "2029-06-26",
|
| "conditions": "Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Biogen",
|
| "company_name": "BIOGEN INC.",
|
| "ticker": "BIIB"
|
| },
|
| {
|
| "asset": "lorlatanib",
|
| "nct_id": "NCT05059522",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-12-31",
|
| "conditions": "Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "lutikizumab",
|
| "nct_id": "NCT06468228",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-12",
|
| "conditions": "Hidradenitis Suppurativa",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AbbVie",
|
| "company_name": "AbbVie Inc.",
|
| "ticker": "ABBV"
|
| },
|
| {
|
| "asset": "maridebart cafraglutide",
|
| "nct_id": "NCT06858839",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-01-21",
|
| "conditions": "Obesity",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Amgen",
|
| "company_name": "AMGEN INC",
|
| "ticker": "AMGN"
|
| },
|
| {
|
| "asset": "maridebart cafraglutide",
|
| "nct_id": "NCT06858878",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-01-21",
|
| "conditions": "Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Amgen",
|
| "company_name": "AMGEN INC",
|
| "ticker": "AMGN"
|
| },
|
| {
|
| "asset": "maridebart cafraglutide",
|
| "nct_id": "NCT06987695",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-04-27",
|
| "conditions": "Obesity Disease",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Amgen",
|
| "company_name": "AMGEN INC",
|
| "ticker": "AMGN"
|
| },
|
| {
|
| "asset": "maridebart cafraglutide",
|
| "nct_id": "NCT07037433",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-06-30",
|
| "conditions": "Atherosclerotic Cardiovascular Disease; Overweight; Obesity",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Amgen",
|
| "company_name": "AMGEN INC",
|
| "ticker": "AMGN"
|
| },
|
| {
|
| "asset": "maridebart cafraglutide",
|
| "nct_id": "NCT07037459",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-06-30",
|
| "conditions": "Heart Failure With Preserved Ejection Fraction; Heart Failure With Mildly Reduced Ejection Fraction; Obesity",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Amgen",
|
| "company_name": "AMGEN INC",
|
| "ticker": "AMGN"
|
| },
|
| {
|
| "asset": "maridebart cafraglutide",
|
| "nct_id": "NCT07225686",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-09-29",
|
| "conditions": "Obesity; Obstructive Sleep Apnea",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Amgen",
|
| "company_name": "AMGEN INC",
|
| "ticker": "AMGN"
|
| },
|
| {
|
| "asset": "maridebart cafraglutide",
|
| "nct_id": "NCT07226765",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-09-29",
|
| "conditions": "Obstructive Sleep Apnea",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Amgen",
|
| "company_name": "AMGEN INC",
|
| "ticker": "AMGN"
|
| },
|
| {
|
| "asset": "maridebart cafraglutide",
|
| "nct_id": "NCT07575399",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-01-03",
|
| "conditions": "Obesity or Overweight",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Amgen",
|
| "company_name": "AMGEN INC",
|
| "ticker": "AMGN"
|
| },
|
| {
|
| "asset": "maridebart cafraglutide",
|
| "nct_id": "NCT07684144",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2027-12-26",
|
| "conditions": "Obesity; Overweight; Diabetes Mellitus, Type 2",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Amgen",
|
| "company_name": "AMGEN INC",
|
| "ticker": "AMGN"
|
| },
|
| {
|
| "asset": "maridebart cafraglutide",
|
| "nct_id": "NCT07684235",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2027-12-26",
|
| "conditions": "Obesity; Overweight",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Amgen",
|
| "company_name": "AMGEN INC",
|
| "ticker": "AMGN"
|
| },
|
| {
|
| "asset": "mercaptopurine",
|
| "nct_id": "NCT03020030",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-11-30",
|
| "conditions": "Acute Lymphoblastic Leukemia, Pediatric",
|
| "arm_role": "other",
|
| "sponsor_raw": "Dana-Farber Cancer Institute",
|
| "company_name": "DANA Inc",
|
| "ticker": "DAN"
|
| },
|
| {
|
| "asset": "mercaptopurine",
|
| "nct_id": "NCT03117751",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-09-30",
|
| "conditions": "Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "St. Jude Children's Research Hospital",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "mevrometostat",
|
| "nct_id": "NCT06551324",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-07-13",
|
| "conditions": "Metastatic Castrate Resistant Prostate Cancer (mCRPC)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "mevrometostat",
|
| "nct_id": "NCT06629779",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-12-02",
|
| "conditions": "Metastatic Castration-Resistant Prostate Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "mevrometostat",
|
| "nct_id": "NCT07028853",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-09-12",
|
| "conditions": "Metastatic Castration Sensitive Prostate Cancer (mCSPC); Hormone Sensitive Prostate Cancer; Prostate Cancer; Cancer of the Prostate",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "mezigdomide",
|
| "nct_id": "NCT05519085",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-01-10",
|
| "conditions": "Relapsed or Refractory Multiple Myeloma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Celgene",
|
| "company_name": "BRISTOL MYERS SQUIBB CO",
|
| "ticker": "BMY"
|
| },
|
| {
|
| "asset": "mezigdomide",
|
| "nct_id": "NCT05552976",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-07-18",
|
| "conditions": "Relapsed or Refractory Multiple Myeloma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Bristol-Myers Squibb",
|
| "company_name": "BRISTOL MYERS SQUIBB CO",
|
| "ticker": "BMY"
|
| },
|
| {
|
| "asset": "mibavademab",
|
| "nct_id": "NCT06548100",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-07-14",
|
| "conditions": "Generalized Lipodystrophy",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Regeneron Pharmaceuticals",
|
| "company_name": "REGENERON PHARMACEUTICALS, INC.",
|
| "ticker": "REGN"
|
| },
|
| {
|
| "asset": "mibavademab",
|
| "nct_id": "NCT07220772",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-06-18",
|
| "conditions": "Monogenic Obesity",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Regeneron Pharmaceuticals",
|
| "company_name": "REGENERON PHARMACEUTICALS, INC.",
|
| "ticker": "REGN"
|
| },
|
| {
|
| "asset": "midazolam",
|
| "nct_id": "NCT05208047",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2025-09-30",
|
| "conditions": "Advanced Gastrointestinal Stromal Tumors; Metastatic Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Cogent Biosciences, Inc.",
|
| "company_name": "Cogent Biosciences, Inc.",
|
| "ticker": "COGT"
|
| },
|
| {
|
| "asset": "midazolam",
|
| "nct_id": "NCT05646862",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-11-13",
|
| "conditions": "Breast Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Hoffmann-La Roche",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "migalastat",
|
| "nct_id": "NCT04020055",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-12-31",
|
| "conditions": "Fabry Disease",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Amicus Therapeutics",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "migalastat",
|
| "nct_id": "NCT05280548",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-05-22",
|
| "conditions": "Fabry Disease",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Sanofi",
|
| "company_name": "Sanofi",
|
| "ticker": "SNY"
|
| },
|
| {
|
| "asset": "migalastat",
|
| "nct_id": "NCT06904261",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-12",
|
| "conditions": "Fabry Disease",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Amicus Therapeutics",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "minoxidil",
|
| "nct_id": "NCT05888922",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-10",
|
| "conditions": "Androgenetic Alopecia; Female Pattern Baldness",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Industrial Farmacéutica Cantabria, S.A.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "minoxidil",
|
| "nct_id": "NCT05888922",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-10",
|
| "conditions": "Androgenetic Alopecia; Female Pattern Baldness",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Industrial Farmacéutica Cantabria, S.A.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "minoxidil",
|
| "nct_id": "NCT06501924",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2025-10-17",
|
| "conditions": "Androgenetic Alopecia; Female Pattern Baldness; Male Pattern Baldness",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Applied Biology, Inc.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "minoxidil",
|
| "nct_id": "NCT07080931",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-12",
|
| "conditions": "Androgenetic Alopecia",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.",
|
| "company_name": "Sunshine Biopharma Inc.",
|
| "ticker": "SBFM"
|
| },
|
| {
|
| "asset": "minoxidil",
|
| "nct_id": "NCT07435012",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-12",
|
| "conditions": "Androgenic Alopecia",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Triple Hair Inc",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "minoxidil",
|
| "nct_id": "NCT07529977",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2028-10-30",
|
| "conditions": "Androgenetic Alopecia; Androgenetic Alopecia (AGA)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eurofarma Laboratorios S.A.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "monalizumab",
|
| "nct_id": "NCT04590963",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2022-05-11",
|
| "conditions": "Squamous Cell Carcinoma of the Head and Neck",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "monalizumab",
|
| "nct_id": "NCT05221840",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-09-30",
|
| "conditions": "Non-Small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "nelarabine",
|
| "nct_id": "NCT03020030",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-11-30",
|
| "conditions": "Acute Lymphoblastic Leukemia, Pediatric",
|
| "arm_role": "other",
|
| "sponsor_raw": "Dana-Farber Cancer Institute",
|
| "company_name": "DANA Inc",
|
| "ticker": "DAN"
|
| },
|
| {
|
| "asset": "nelarabine",
|
| "nct_id": "NCT03117751",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-09-30",
|
| "conditions": "Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "St. Jude Children's Research Hospital",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "nemtabrutinib",
|
| "nct_id": "NCT05624554",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-05-19",
|
| "conditions": "Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "nemtabrutinib",
|
| "nct_id": "NCT05947851",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2032-06-01",
|
| "conditions": "Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Chronic Lymphocytic; Small-Cell Lymphoma; Lymphoma, Small Lymphocytic; CLL; SLL",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "nemtabrutinib",
|
| "nct_id": "NCT06136559",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2032-09-07",
|
| "conditions": "Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "niraparib",
|
| "nct_id": "NCT02655016",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2019-05-17",
|
| "conditions": "Ovarian Neoplasms",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Tesaro, Inc.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "niraparib",
|
| "nct_id": "NCT03602859",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2024-10-31",
|
| "conditions": "Ovarian Neoplasms; Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Tesaro, Inc.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "niraparib",
|
| "nct_id": "NCT03651206",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-06",
|
| "conditions": "Ovarian Carcinosarcoma; Endometrial Carcinosarcoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "ARCAGY/ GINECO GROUP",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "niraparib",
|
| "nct_id": "NCT03748641",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2021-10-08",
|
| "conditions": "Castration-Resistant Prostatic Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Janssen Research & Development, LLC",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "niraparib",
|
| "nct_id": "NCT03768063",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2028-07-05",
|
| "conditions": "Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Hoffmann-La Roche",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "niraparib",
|
| "nct_id": "NCT03981796",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-11-26",
|
| "conditions": "Neoplasms",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Tesaro, Inc.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "niraparib",
|
| "nct_id": "NCT04497844",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2025-01-07",
|
| "conditions": "Metastatic Castration-sensitive Prostate Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Janssen Research & Development, LLC",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "niraparib",
|
| "nct_id": "NCT04915755",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2024-06-28",
|
| "conditions": "Neoplasms, Breast",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "GlaxoSmithKline",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "niraparib",
|
| "nct_id": "NCT05615818",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-06",
|
| "conditions": "Biliary Tract Neoplasms",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "UNICANCER",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "niraparib",
|
| "nct_id": "NCT06388733",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-12",
|
| "conditions": "Glioblastoma; GBM; Brain Neoplasms, Adult, Malignant; Brain Tumor",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Ivy Brain Tumor Center",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "niraparib",
|
| "nct_id": "NCT06915025",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2032-10-31",
|
| "conditions": "Epithelial Ovarian Cancer; Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Imunon",
|
| "company_name": "Imunon, Inc.",
|
| "ticker": "IMNN"
|
| },
|
| {
|
| "asset": "obicetrapib",
|
| "nct_id": "NCT05202509",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-11",
|
| "conditions": "Atherosclerotic Cardiovascular Disease",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "NewAmsterdam Pharma",
|
| "company_name": "NewAmsterdam Pharma Co N.V.",
|
| "ticker": "NAMS"
|
| },
|
| {
|
| "asset": "obicetrapib",
|
| "nct_id": "NCT07219602",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-03",
|
| "conditions": "Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "NewAmsterdam Pharma",
|
| "company_name": "NewAmsterdam Pharma Co N.V.",
|
| "ticker": "NAMS"
|
| },
|
| {
|
| "asset": "oleclumab",
|
| "nct_id": "NCT05221840",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-09-30",
|
| "conditions": "Non-Small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "olezarsen",
|
| "nct_id": "NCT05681351",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-03",
|
| "conditions": "Severe Hypertriglyceridemia",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Ionis Pharmaceuticals, Inc.",
|
| "company_name": "IONIS PHARMACEUTICALS INC",
|
| "ticker": "IONS"
|
| },
|
| {
|
| "asset": "olverembatinib",
|
| "nct_id": "NCT06051409",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-12-31",
|
| "conditions": "Ph+ ALL; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Ascentage Pharma Group Inc.",
|
| "company_name": "ASCENTAGE PHARMA GROUP INTERNATIONAL",
|
| "ticker": "AAPG"
|
| },
|
| {
|
| "asset": "olverembatinib",
|
| "nct_id": "NCT06423911",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2025-12",
|
| "conditions": "Chronic Myeloid Leukemia; CML; CML, Chronic Phase",
|
| "arm_role": "other",
|
| "sponsor_raw": "Ascentage Pharma Group Inc.",
|
| "company_name": "ASCENTAGE PHARMA GROUP INTERNATIONAL",
|
| "ticker": "AAPG"
|
| },
|
| {
|
| "asset": "olverembatinib",
|
| "nct_id": "NCT06640361",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-03-31",
|
| "conditions": "GIST",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Ascentage Pharma Group Inc.",
|
| "company_name": "ASCENTAGE PHARMA GROUP INTERNATIONAL",
|
| "ticker": "AAPG"
|
| },
|
| {
|
| "asset": "olvimulogene nanivacirepvec",
|
| "nct_id": "NCT05281471",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-12",
|
| "conditions": "Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; High-grade Serous Ovarian Cancer; Endometrioid Ovarian Cancer; Ovarian Clear Cell Carcinoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Genelux Corporation",
|
| "company_name": "GENELUX Corp",
|
| "ticker": "GNLX"
|
| },
|
| {
|
| "asset": "orforglipron",
|
| "nct_id": "NCT05869903",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2025-07-25",
|
| "conditions": "Obesity; Overweight; Overweight or Obesity",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "orforglipron",
|
| "nct_id": "NCT06649045",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-11",
|
| "conditions": "OSA; Overweight or Obesity",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "orforglipron",
|
| "nct_id": "NCT06672549",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-02",
|
| "conditions": "Obesity; Overweight",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "orforglipron",
|
| "nct_id": "NCT06672939",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-12",
|
| "conditions": "Obesity; Overweight",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "orforglipron",
|
| "nct_id": "NCT06948422",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-09",
|
| "conditions": "Hypertension",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "orforglipron",
|
| "nct_id": "NCT06948435",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-09",
|
| "conditions": "Hypertension; Overweight or Obesity",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "orforglipron",
|
| "nct_id": "NCT06952530",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-09",
|
| "conditions": "Hypertension",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "orforglipron",
|
| "nct_id": "NCT06972459",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-08",
|
| "conditions": "Obesity; Overweight",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "orforglipron",
|
| "nct_id": "NCT06972472",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-08",
|
| "conditions": "Obesity; Overweight; Type 2 Diabetes",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "orforglipron",
|
| "nct_id": "NCT06993792",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-08",
|
| "conditions": "Obesity; Overweight; Type 2 Diabetes",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "orforglipron",
|
| "nct_id": "NCT07153471",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-04",
|
| "conditions": "Osteoarthritis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "orforglipron",
|
| "nct_id": "NCT07202884",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-03",
|
| "conditions": "Urinary Incontinence,Stress",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "orforglipron",
|
| "nct_id": "NCT07223593",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-06",
|
| "conditions": "Peripheral Arterial Disease",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "orforglipron",
|
| "nct_id": "NCT07241390",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2031-08",
|
| "conditions": "Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "orforglipron",
|
| "nct_id": "NCT07613307",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2027-05",
|
| "conditions": "Diabetes Mellitus, Type 2; Diabetes Melletus; Glucose Metabolism Disorders; Metabolic Disorders; Nutritional and Metabolic Diseases; Endocrine System Diseases; Feeding Behavior; Behavior; Fasting; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptide Receptors; Receptors, G-Protein-Coupled; Receptors, Cell Surface; Membrane Proteins; Proteins; Receptors, Peptide",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "orforglipron",
|
| "nct_id": "NCT07668336",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2030-03",
|
| "conditions": "Diabetes Mellitus, Type 2",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "paltusotine",
|
| "nct_id": "NCT07087054",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-08",
|
| "conditions": "Carcinoid Syndrome; Carcinoid; Carcinoid Tumor; Carcinoid Tumor of Ileum; Carcinoid Tumor of Cecum; Carcinoid Tumor of Liver; Carcinoid Tumor of Pancreas; Carcinoid Syndrome Diarrhea; Carcinoid Intestine Tumor",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Crinetics Pharmaceuticals Inc.",
|
| "company_name": "Crinetics Pharmaceuticals, Inc.",
|
| "ticker": "CRNX"
|
| },
|
| {
|
| "asset": "patidegib",
|
| "nct_id": "NCT06050122",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-08",
|
| "conditions": "Gorlin Syndrome",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Sol-Gel Technologies, Ltd.",
|
| "company_name": "Sol-Gel Technologies Ltd.",
|
| "ticker": "SLGL"
|
| },
|
| {
|
| "asset": "pazopanib",
|
| "nct_id": "NCT03592472",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-12-30",
|
| "conditions": "Renal Cell Carcinoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Xynomic Pharmaceuticals, Inc.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "pazopanib",
|
| "nct_id": "NCT06263231",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-12",
|
| "conditions": "Sarcoma,Soft Tissue",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Intensity Therapeutics, Inc.",
|
| "company_name": "INTENSITY THERAPEUTICS, INC.",
|
| "ticker": "INTS"
|
| },
|
| {
|
| "asset": "pegaspargase",
|
| "nct_id": "NCT03020030",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-11-30",
|
| "conditions": "Acute Lymphoblastic Leukemia, Pediatric",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Dana-Farber Cancer Institute",
|
| "company_name": "DANA Inc",
|
| "ticker": "DAN"
|
| },
|
| {
|
| "asset": "pegaspargase",
|
| "nct_id": "NCT03117751",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-09-30",
|
| "conditions": "Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "St. Jude Children's Research Hospital",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "pegaspargase",
|
| "nct_id": "NCT05700448",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2029-12",
|
| "conditions": "Extranodal NK/T-cell Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "CStone Pharmaceuticals",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "pelabresib",
|
| "nct_id": "NCT06401356",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-06-02",
|
| "conditions": "Hematologic Malignancy; Solid Tumor; Advanced Malignancies",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novartis Pharmaceuticals",
|
| "company_name": "NOVARTIS AG",
|
| "ticker": "NVS"
|
| },
|
| {
|
| "asset": "pitolisant",
|
| "nct_id": "NCT06366464",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-07",
|
| "conditions": "Prader-Willi Syndrome",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Harmony Biosciences Management, Inc.",
|
| "company_name": "Harmony Biosciences Holdings, Inc.",
|
| "ticker": "HRMY"
|
| },
|
| {
|
| "asset": "pitolisant",
|
| "nct_id": "NCT07219485",
|
| "phase": "PHASE3",
|
| "status": "ENROLLING_BY_INVITATION",
|
| "primary_completion": "2030-08",
|
| "conditions": "Prader-Willi Syndrome",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Harmony Biosciences Management, Inc.",
|
| "company_name": "Harmony Biosciences Holdings, Inc.",
|
| "ticker": "HRMY"
|
| },
|
| {
|
| "asset": "povorcitinib",
|
| "nct_id": "NCT06113445",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-02-24",
|
| "conditions": "NonSegmental Vitiligo",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Incyte Corporation",
|
| "company_name": "INCYTE CORP",
|
| "ticker": "INCY"
|
| },
|
| {
|
| "asset": "povorcitinib",
|
| "nct_id": "NCT06113471",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-03-17",
|
| "conditions": "NonSegmental Vitiligo",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Incyte Corporation",
|
| "company_name": "INCYTE CORP",
|
| "ticker": "INCY"
|
| },
|
| {
|
| "asset": "povorcitinib",
|
| "nct_id": "NCT06212999",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-12-26",
|
| "conditions": "Hidradenitis Suppurativa (HS)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Incyte Corporation",
|
| "company_name": "INCYTE CORP",
|
| "ticker": "INCY"
|
| },
|
| {
|
| "asset": "povorcitinib",
|
| "nct_id": "NCT06855498",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-02-28",
|
| "conditions": "Hidradenitis Suppurativa (HS)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Incyte Corporation",
|
| "company_name": "INCYTE CORP",
|
| "ticker": "INCY"
|
| },
|
| {
|
| "asset": "ralinepag",
|
| "nct_id": "NCT03683186",
|
| "phase": "PHASE3",
|
| "status": "ENROLLING_BY_INVITATION",
|
| "primary_completion": "2026-12",
|
| "conditions": "PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension; Hypertension; Connective Tissue Diseases; Familial Primary Pulmonary Hypertension; Vascular Diseases; Cardiovascular Diseases; Hypertension, Pulmonary; Lung Diseases; Respiratory Tract Disease",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "United Therapeutics",
|
| "company_name": "UNITED THERAPEUTICS Corp",
|
| "ticker": "UTHR"
|
| },
|
| {
|
| "asset": "ravulizumab",
|
| "nct_id": "NCT05644561",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-07-15",
|
| "conditions": "Generalized Myasthenia Gravis; gMG",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Alexion Pharmaceuticals, Inc.",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "ravulizumab",
|
| "nct_id": "NCT07024563",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-07-12",
|
| "conditions": "IgAN; IgAVN; Immunoglobulin A Nephropathy; Immunoglobulin A Vasculitis Associated Nephritis; Henoch-schonlein Purpura Nephritis; IgA Vasculitis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Alexion Pharmaceuticals, Inc.",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "ravulizumab",
|
| "nct_id": "NCT07596784",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2027-08-27",
|
| "conditions": "Generalized Myasthenia Gravis; gMG",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Alexion Pharmaceuticals, Inc.",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "recombinant human tissue kallikrein",
|
| "nct_id": "NCT05065216",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-12",
|
| "conditions": "Acute Stroke; Ischemic Stroke; Stroke",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "DiaMedica Therapeutics Inc",
|
| "company_name": "DiaMedica Therapeutics Inc.",
|
| "ticker": "DMAC"
|
| },
|
| {
|
| "asset": "rescue medications",
|
| "nct_id": "NCT06132958",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2028-01-10",
|
| "conditions": "Endometrial Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "rescue medications",
|
| "nct_id": "NCT06356311",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-01-04",
|
| "conditions": "Gastroesophageal Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "rescue medications",
|
| "nct_id": "NCT07216703",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2031-10-29",
|
| "conditions": "Cervical Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "rescue medications",
|
| "nct_id": "NCT07318558",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2033-02-25",
|
| "conditions": "Ovarian Neoplasms; Ovarian Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "resmetirom",
|
| "nct_id": "NCT03900429",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2028-01",
|
| "conditions": "NASH - Nonalcoholic Steatohepatitis",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Madrigal Pharmaceuticals, Inc.",
|
| "company_name": "MADRIGAL PHARMACEUTICALS, INC.",
|
| "ticker": "MDGL"
|
| },
|
| {
|
| "asset": "resmetirom",
|
| "nct_id": "NCT04951219",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-03",
|
| "conditions": "Non-Alcoholic Fatty Liver Disease",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Madrigal Pharmaceuticals, Inc.",
|
| "company_name": "MADRIGAL PHARMACEUTICALS, INC.",
|
| "ticker": "MDGL"
|
| },
|
| {
|
| "asset": "resmetirom",
|
| "nct_id": "NCT05500222",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-12",
|
| "conditions": "NASH; Cirrhosis, Liver",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Madrigal Pharmaceuticals, Inc.",
|
| "company_name": "MADRIGAL PHARMACEUTICALS, INC.",
|
| "ticker": "MDGL"
|
| },
|
| {
|
| "asset": "retatrutide",
|
| "nct_id": "NCT05882045",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-04-16",
|
| "conditions": "Obesity; Cardiovascular Diseases",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "retatrutide",
|
| "nct_id": "NCT05929079",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-05",
|
| "conditions": "Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "retatrutide",
|
| "nct_id": "NCT06260722",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-08",
|
| "conditions": "Diabetes Mellitus, Type 2",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "retatrutide",
|
| "nct_id": "NCT06297603",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-10",
|
| "conditions": "Type 2 Diabetes",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "retatrutide",
|
| "nct_id": "NCT06383390",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2029-02",
|
| "conditions": "Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "retatrutide",
|
| "nct_id": "NCT06662383",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-12",
|
| "conditions": "Obesity",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "retatrutide",
|
| "nct_id": "NCT06859268",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2028-04",
|
| "conditions": "Obesity",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "retatrutide",
|
| "nct_id": "NCT07035093",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-09",
|
| "conditions": "Obesity; Overweight; Chronic Low Back Pain (CLBP)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "retatrutide",
|
| "nct_id": "NCT07165028",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2030-08",
|
| "conditions": "Metabolic Dysfunction-Associated Steatotic Liver Disease",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "retatrutide",
|
| "nct_id": "NCT07232719",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-07",
|
| "conditions": "Obesity; Overweight",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "retatrutide",
|
| "nct_id": "NCT07357415",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2028-10",
|
| "conditions": "Obesity; Overweight",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "rezvilutamide",
|
| "nct_id": "NCT07241416",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-03",
|
| "conditions": "Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Jiangsu HengRui Medicine Co., Ltd.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "rezvilutamide",
|
| "nct_id": "NCT07611110",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-02-13",
|
| "conditions": "Metastatic Castration-resistant Prostate Cancer",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "rilvegostomig",
|
| "nct_id": "NCT06109779",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2029-01-02",
|
| "conditions": "Biliary Tract Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "rilvegostomig",
|
| "nct_id": "NCT06357533",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-12-28",
|
| "conditions": "Non-Small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "rilvegostomig",
|
| "nct_id": "NCT06467357",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-06-12",
|
| "conditions": "Biliary Tract Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "rilvegostomig",
|
| "nct_id": "NCT06564844",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-06-30",
|
| "conditions": "Non-small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "rilvegostomig",
|
| "nct_id": "NCT06627647",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2030-11-18",
|
| "conditions": "Non-squamous Non-small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "rilvegostomig",
|
| "nct_id": "NCT06692738",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2030-07-01",
|
| "conditions": "Non-small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "rilvegostomig",
|
| "nct_id": "NCT06764875",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-04-27",
|
| "conditions": "HER2-positive Gastric Cancer; Gastroesophageal Junction Adenocarcinoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "rilvegostomig",
|
| "nct_id": "NCT06868277",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2030-01-17",
|
| "conditions": "Carcinoma, Non-Small Cell Lung",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "rilvegostomig",
|
| "nct_id": "NCT06921785",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-03-16",
|
| "conditions": "Hepatocellular Carcinoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "rilvegostomig",
|
| "nct_id": "NCT06989112",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-01-19",
|
| "conditions": "Endometrial Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "rilvegostomig",
|
| "nct_id": "NCT07221253",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-07-31",
|
| "conditions": "Biliary Tract Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "rilvegostomig",
|
| "nct_id": "NCT07431281",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-08-16",
|
| "conditions": "Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "rina",
|
| "nct_id": "NCT06619236",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-02",
|
| "conditions": "Platinum-resistant Ovarian Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Genmab",
|
| "company_name": "GENMAB A/S",
|
| "ticker": "GMAB"
|
| },
|
| {
|
| "asset": "rina",
|
| "nct_id": "NCT07166094",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-08",
|
| "conditions": "Endometrial Cancer; Recurrent or Progressive Endometrial Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Genmab",
|
| "company_name": "GENMAB A/S",
|
| "ticker": "GMAB"
|
| },
|
| {
|
| "asset": "rina",
|
| "nct_id": "NCT07225270",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-10",
|
| "conditions": "Ovarian Cancer; Platinum-sensitive Ovarian Cancer; PSOC",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Genmab",
|
| "company_name": "GENMAB A/S",
|
| "ticker": "GMAB"
|
| },
|
| {
|
| "asset": "rina",
|
| "nct_id": "NCT07564141",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2029-12",
|
| "conditions": "Platinum-Sensitive Ovarian Cancer; Ovarian Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Genmab",
|
| "company_name": "GENMAB A/S",
|
| "ticker": "GMAB"
|
| },
|
| {
|
| "asset": "rina",
|
| "nct_id": "NCT07604766",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2027-09",
|
| "conditions": "Platinum-resistant Ovarian Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Genmab",
|
| "company_name": "GENMAB A/S",
|
| "ticker": "GMAB"
|
| },
|
| {
|
| "asset": "ritlecitinib",
|
| "nct_id": "NCT06072183",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-07-30",
|
| "conditions": "Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "ritlecitinib",
|
| "nct_id": "NCT06072183",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-07-30",
|
| "conditions": "Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "ritlecitinib",
|
| "nct_id": "NCT06072183",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-07-30",
|
| "conditions": "Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "ritlecitinib",
|
| "nct_id": "NCT06072183",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-07-30",
|
| "conditions": "Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "ritlecitinib",
|
| "nct_id": "NCT06163326",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-03-31",
|
| "conditions": "Vitiligo",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "ritlecitinib",
|
| "nct_id": "NCT06163326",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-03-31",
|
| "conditions": "Vitiligo",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "ritlecitinib",
|
| "nct_id": "NCT06873945",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-12-21",
|
| "conditions": "Alopecia Areata",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "ritlecitinib",
|
| "nct_id": "NCT06873945",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-12-21",
|
| "conditions": "Alopecia Areata",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "ritlecitinib higher",
|
| "nct_id": "NCT07029711",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-12-02",
|
| "conditions": "Severe Alopecia Areata",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "ritlecitinib higher",
|
| "nct_id": "NCT07029828",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2030-06-26",
|
| "conditions": "Severe Alopecia Areata",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "ritlecitinib lower",
|
| "nct_id": "NCT07029711",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-12-02",
|
| "conditions": "Severe Alopecia Areata",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "ritlecitinib lower",
|
| "nct_id": "NCT07029828",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2030-06-26",
|
| "conditions": "Severe Alopecia Areata",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "rosuvastatin calcium",
|
| "nct_id": "NCT03016819",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-12",
|
| "conditions": "Alveolar Soft Part Sarcoma; Leiomyosarcoma; Synovial Sarcoma; Soft-Tissue Sarcoma",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Advenchen Laboratories, LLC",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "rosuvastatin calcium",
|
| "nct_id": "NCT04602754",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-05",
|
| "conditions": "Dyslipidemia Associated With Type II Diabetes Mellitus",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "EMS",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "rosuvastatin calcium",
|
| "nct_id": "NCT07216482",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-12-02",
|
| "conditions": "Hyperlipidemia",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "rosuvastatin calcium",
|
| "nct_id": "NCT07474649",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2028-06-01",
|
| "conditions": "Coronary Atherosclerosis; Mixed Dyslipidemia; Hypercholesterolemia",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Daiichi Sankyo",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "sacituzumab govitecan hziy",
|
| "nct_id": "NCT04639986",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-12",
|
| "conditions": "Metastatic Breast Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Gilead Sciences",
|
| "company_name": "GILEAD SCIENCES, INC.",
|
| "ticker": "GILD"
|
| },
|
| {
|
| "asset": "sacituzumab govitecan hziy",
|
| "nct_id": "NCT05089734",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2023-11-29",
|
| "conditions": "Non-Small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Gilead Sciences",
|
| "company_name": "GILEAD SCIENCES, INC.",
|
| "ticker": "GILD"
|
| },
|
| {
|
| "asset": "sacituzumab govitecan hziy",
|
| "nct_id": "NCT05382286",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-02",
|
| "conditions": "Triple Negative Breast Cancer; PD-L1 Positive",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Gilead Sciences",
|
| "company_name": "GILEAD SCIENCES, INC.",
|
| "ticker": "GILD"
|
| },
|
| {
|
| "asset": "sacituzumab govitecan hziy",
|
| "nct_id": "NCT05382299",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2028-07",
|
| "conditions": "Triple Negative Breast Cancer; PD-L1 Negative",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Gilead Sciences",
|
| "company_name": "GILEAD SCIENCES, INC.",
|
| "ticker": "GILD"
|
| },
|
| {
|
| "asset": "sacituzumab govitecan hziy",
|
| "nct_id": "NCT05633654",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-06",
|
| "conditions": "Triple Negative Breast Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Gilead Sciences",
|
| "company_name": "GILEAD SCIENCES, INC.",
|
| "ticker": "GILD"
|
| },
|
| {
|
| "asset": "sacituzumab govitecan hziy",
|
| "nct_id": "NCT05840211",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2028-04",
|
| "conditions": "Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Gilead Sciences",
|
| "company_name": "GILEAD SCIENCES, INC.",
|
| "ticker": "GILD"
|
| },
|
| {
|
| "asset": "sacituzumab govitecan hziy",
|
| "nct_id": "NCT06486441",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2029-06",
|
| "conditions": "Endometrial Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Gilead Sciences",
|
| "company_name": "GILEAD SCIENCES, INC.",
|
| "ticker": "GILD"
|
| },
|
| {
|
| "asset": "setmelanotide",
|
| "nct_id": "NCT05093634",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2025-12-22",
|
| "conditions": "Obesity; Genetic Obesity",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Rhythm Pharmaceuticals, Inc.",
|
| "company_name": "RHYTHM PHARMACEUTICALS, INC.",
|
| "ticker": "RYTM"
|
| },
|
| {
|
| "asset": "setmelanotide",
|
| "nct_id": "NCT05774756",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2025-03-18",
|
| "conditions": "Hypothalamic Obesity",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Rhythm Pharmaceuticals, Inc.",
|
| "company_name": "RHYTHM PHARMACEUTICALS, INC.",
|
| "ticker": "RYTM"
|
| },
|
| {
|
| "asset": "setmelanotide",
|
| "nct_id": "NCT06760546",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-03-13",
|
| "conditions": "Hypothalamic Obesity; Multiple Pituitary Hormone Deficiency Genetic Form; Septo-Optic Dysplasia; Optic Nerve Hypoplasia; Childhood-onset Combined Pituitary Hormone Deficiency; Pituitary Stalk Interruption Syndrome",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Rhythm Pharmaceuticals, Inc.",
|
| "company_name": "RHYTHM PHARMACEUTICALS, INC.",
|
| "ticker": "RYTM"
|
| },
|
| {
|
| "asset": "sonelokimab",
|
| "nct_id": "NCT06641076",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-02-04",
|
| "conditions": "Arthritis, Psoriatic",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "MoonLake Immunotherapeutics AG",
|
| "company_name": "MoonLake Immunotherapeutics",
|
| "ticker": "MLTX"
|
| },
|
| {
|
| "asset": "sonelokimab",
|
| "nct_id": "NCT06641089",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-01-15",
|
| "conditions": "Arthritis, Psoriatic",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "MoonLake Immunotherapeutics AG",
|
| "company_name": "MoonLake Immunotherapeutics",
|
| "ticker": "MLTX"
|
| },
|
| {
|
| "asset": "sonelokimab",
|
| "nct_id": "NCT06768671",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-09-28",
|
| "conditions": "Hidradenitis Suppurativa",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "MoonLake Immunotherapeutics AG",
|
| "company_name": "MoonLake Immunotherapeutics",
|
| "ticker": "MLTX"
|
| },
|
| {
|
| "asset": "sonelokimab",
|
| "nct_id": "NCT07007637",
|
| "phase": "PHASE3",
|
| "status": "ENROLLING_BY_INVITATION",
|
| "primary_completion": "2028-06-13",
|
| "conditions": "Hidradenitis Suppurativa",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "MoonLake Immunotherapeutics AG",
|
| "company_name": "MoonLake Immunotherapeutics",
|
| "ticker": "MLTX"
|
| },
|
| {
|
| "asset": "sonelokimab",
|
| "nct_id": "NCT07223138",
|
| "phase": "PHASE3",
|
| "status": "ENROLLING_BY_INVITATION",
|
| "primary_completion": "2028-02-04",
|
| "conditions": "Arthritis, Psoriatic",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "MoonLake Immunotherapeutics AG",
|
| "company_name": "MoonLake Immunotherapeutics",
|
| "ticker": "MLTX"
|
| },
|
| {
|
| "asset": "sotagliflozin",
|
| "nct_id": "NCT06217302",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-12",
|
| "conditions": "Diabetic Nephropathies; Kidney Failure, Chronic; Diabetes Mellitus Type 1; Heart Failure",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Alessandro Doria",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "sotagliflozin",
|
| "nct_id": "NCT06481891",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-07",
|
| "conditions": "Obstructive Cardiomyopathy, Hypertrophic; Non-obstructive Hypertrophic Cardiomyopathy",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Lexicon Pharmaceuticals",
|
| "company_name": "LEXICON PHARMACEUTICALS, INC.",
|
| "ticker": "LXRX"
|
| },
|
| {
|
| "asset": "sotorasib",
|
| "nct_id": "NCT04303780",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2022-08-02",
|
| "conditions": "KRAS p, G12c Mutated /Advanced Metastatic NSCLC",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Amgen",
|
| "company_name": "AMGEN INC",
|
| "ticker": "AMGN"
|
| },
|
| {
|
| "asset": "sotorasib",
|
| "nct_id": "NCT05920356",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-06-30",
|
| "conditions": "Non-Small Cell Lung Cancer (NSCLC)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Amgen",
|
| "company_name": "AMGEN INC",
|
| "ticker": "AMGN"
|
| },
|
| {
|
| "asset": "sotorasib",
|
| "nct_id": "NCT06252649",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-09-25",
|
| "conditions": "Metastatic Colorectal Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Amgen",
|
| "company_name": "AMGEN INC",
|
| "ticker": "AMGN"
|
| },
|
| {
|
| "asset": "sotorasib",
|
| "nct_id": "NCT06497556",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-05-19",
|
| "conditions": "Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Hoffmann-La Roche",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "supportive care measures",
|
| "nct_id": "NCT06170788",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-01-25",
|
| "conditions": "Non-small Cell Lung Cancer (NSCLC)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "supportive care measures",
|
| "nct_id": "NCT06356311",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-01-04",
|
| "conditions": "Gastroesophageal Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "tafasitamab",
|
| "nct_id": "NCT04680052",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2024-02-23",
|
| "conditions": "Follicular Lymphoma; Marginal Zone Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Incyte Corporation",
|
| "company_name": "INCYTE CORP",
|
| "ticker": "INCY"
|
| },
|
| {
|
| "asset": "tafasitamab",
|
| "nct_id": "NCT04824092",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-09-01",
|
| "conditions": "Diffuse Large B-cell Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Incyte Corporation",
|
| "company_name": "INCYTE CORP",
|
| "ticker": "INCY"
|
| },
|
| {
|
| "asset": "tafasitamab",
|
| "nct_id": "NCT05429268",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-03-30",
|
| "conditions": "Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Incyte Corporation",
|
| "company_name": "INCYTE CORP",
|
| "ticker": "INCY"
|
| },
|
| {
|
| "asset": "tafasitamab",
|
| "nct_id": "NCT06521255",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-09",
|
| "conditions": "DLBCL",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Beijing InnoCare Pharma Tech Co., Ltd.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "talazoparib",
|
| "nct_id": "NCT05059522",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-12-31",
|
| "conditions": "Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "tapinarof",
|
| "nct_id": "NCT05172726",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-10",
|
| "conditions": "Plaque Psoriasis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Organon and Co",
|
| "company_name": "Organon & Co.",
|
| "ticker": "OGN"
|
| },
|
| {
|
| "asset": "tapinarof",
|
| "nct_id": "NCT05981118",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "ENROLLING_BY_INVITATION",
|
| "primary_completion": "2026-07",
|
| "conditions": "ICD10 Code L40.9 for Psoriasis",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Wake Forest University Health Sciences",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "tapinarof",
|
| "nct_id": "NCT07265479",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-01",
|
| "conditions": "Atopic Dermatitis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Organon and Co",
|
| "company_name": "Organon & Co.",
|
| "ticker": "OGN"
|
| },
|
| {
|
| "asset": "tarlatamab",
|
| "nct_id": "NCT05740566",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2025-01-29",
|
| "conditions": "Small Cell Lung Cancer (SCLC)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Amgen",
|
| "company_name": "AMGEN INC",
|
| "ticker": "AMGN"
|
| },
|
| {
|
| "asset": "tarlatamab",
|
| "nct_id": "NCT06117774",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2030-04-20",
|
| "conditions": "Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Amgen",
|
| "company_name": "AMGEN INC",
|
| "ticker": "AMGN"
|
| },
|
| {
|
| "asset": "tarlatamab",
|
| "nct_id": "NCT06211036",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-07-05",
|
| "conditions": "Extensive-Stage Small-Cell Lung Cancer; Small-Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Amgen",
|
| "company_name": "AMGEN INC",
|
| "ticker": "AMGN"
|
| },
|
| {
|
| "asset": "tarlatamab",
|
| "nct_id": "NCT07005128",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-01-04",
|
| "conditions": "Small-cell Lung Cancer; Extensive Stage Small-cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Amgen",
|
| "company_name": "AMGEN INC",
|
| "ticker": "AMGN"
|
| },
|
| {
|
| "asset": "tarlatamab",
|
| "nct_id": "NCT07637513",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2037-11",
|
| "conditions": "Limited Stage Small-Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "PrECOG, LLC.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "telisotuzumab adizutecan",
|
| "nct_id": "NCT06614192",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-08",
|
| "conditions": "Metastatic Colorectal Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AbbVie",
|
| "company_name": "AbbVie Inc.",
|
| "ticker": "ABBV"
|
| },
|
| {
|
| "asset": "telisotuzumab adizutecan",
|
| "nct_id": "NCT07005102",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2031-12",
|
| "conditions": "Non-Squamous Non-Small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AbbVie",
|
| "company_name": "AbbVie Inc.",
|
| "ticker": "ABBV"
|
| },
|
| {
|
| "asset": "telisotuzumab adizutecan",
|
| "nct_id": "NCT07155187",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2030-09",
|
| "conditions": "Non-Small Cell Lung Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AbbVie",
|
| "company_name": "AbbVie Inc.",
|
| "ticker": "ABBV"
|
| },
|
| {
|
| "asset": "telisotuzumab adizutecan",
|
| "nct_id": "NCT07525206",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-05",
|
| "conditions": "Colorectal Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AbbVie",
|
| "company_name": "AbbVie Inc.",
|
| "ticker": "ABBV"
|
| },
|
| {
|
| "asset": "telitacicept",
|
| "nct_id": "NCT06456580",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-05",
|
| "conditions": "Generalized Myasthenia Gravis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Vor Biopharma",
|
| "company_name": "Vor Biopharma Inc.",
|
| "ticker": "VOR"
|
| },
|
| {
|
| "asset": "telitacicept",
|
| "nct_id": "NCT07249632",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-12-31",
|
| "conditions": "Myasthenia Gravis, Ocular",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "RemeGen Co., Ltd.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "tezepelumab",
|
| "nct_id": "NCT06023589",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-05-31",
|
| "conditions": "Asthma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "tezepelumab",
|
| "nct_id": "NCT06740045",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2025-03",
|
| "conditions": "Asthma; Chronic Rhinosinusitis With Nasal Polyps",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Dr. Andrew Thamboo, MD",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "tezepelumab",
|
| "nct_id": "NCT07013123",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2029-08-18",
|
| "conditions": "Severe Asthma; Allergy to House Dust Mites",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "University Hospital, Montpellier",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "tezepelumab",
|
| "nct_id": "NCT07302516",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2028-12",
|
| "conditions": "Asthma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Qilu Pharmaceutical Co., Ltd.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "tezepelumab",
|
| "nct_id": "NCT07363642",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-08-07",
|
| "conditions": "Severe Asthma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "AstraZeneca",
|
| "company_name": "ASTRAZENECA PLC",
|
| "ticker": "AZN"
|
| },
|
| {
|
| "asset": "tirzepatide",
|
| "nct_id": "NCT05556512",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-10",
|
| "conditions": "Obesity; Overweight",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "tirzepatide",
|
| "nct_id": "NCT06075667",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-06-02",
|
| "conditions": "Obesity; Overweight",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "tirzepatide",
|
| "nct_id": "NCT06439277",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-10",
|
| "conditions": "Obesity; Weight Gain",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "tirzepatide",
|
| "nct_id": "NCT06662383",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-12",
|
| "conditions": "Obesity",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "tirzepatide",
|
| "nct_id": "NCT06914895",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-11",
|
| "conditions": "Type 1 Diabetes; Obesity; Overweight",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "tirzepatide",
|
| "nct_id": "NCT06937086",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-04",
|
| "conditions": "Ulcerative Colitis; Obesity or Overweight",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "tirzepatide",
|
| "nct_id": "NCT06937099",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-05",
|
| "conditions": "Crohn's Disease; Obesity or Overweight",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "tirzepatide",
|
| "nct_id": "NCT06962280",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-11",
|
| "conditions": "Type 1 Diabetes; Obesity; Overweight",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "tirzepatide",
|
| "nct_id": "NCT07165028",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2030-08",
|
| "conditions": "Metabolic Dysfunction-Associated Steatotic Liver Disease",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Eli Lilly and Company",
|
| "company_name": "ELI LILLY & Co",
|
| "ticker": "LLY"
|
| },
|
| {
|
| "asset": "tirzepatide",
|
| "nct_id": "NCT07481747",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-02-14",
|
| "conditions": "Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Hudson Biotech",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "tisagenlecleucel",
|
| "nct_id": "NCT04094311",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-03-31",
|
| "conditions": "B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novartis Pharmaceuticals",
|
| "company_name": "NOVARTIS AG",
|
| "ticker": "NVS"
|
| },
|
| {
|
| "asset": "tisagenlecleucel",
|
| "nct_id": "NCT05888493",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2028-07-25",
|
| "conditions": "Follicular Lymphoma (FL)",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novartis Pharmaceuticals",
|
| "company_name": "NOVARTIS AG",
|
| "ticker": "NVS"
|
| },
|
| {
|
| "asset": "tocilizumab",
|
| "nct_id": "NCT04408638",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2028-03-31",
|
| "conditions": "Diffuse Large B-cell Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Hoffmann-La Roche",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "tocilizumab",
|
| "nct_id": "NCT04888221",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2025-01-29",
|
| "conditions": "Giant Cell Arteritis; Neurovascular Disorder",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Assistance Publique - Hôpitaux de Paris",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "tocilizumab",
|
| "nct_id": "NCT05171647",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2025-02-17",
|
| "conditions": "Non-Hodgkin Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Hoffmann-La Roche",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "tocilizumab",
|
| "nct_id": "NCT06084936",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-08-31",
|
| "conditions": "Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Hoffmann-La Roche",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "tocilizumab",
|
| "nct_id": "NCT07570173",
|
| "phase": "PHASE2;PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2033-10-18",
|
| "conditions": "B-cell Acute Lymphoblastic Leukemia",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "tofacitinib",
|
| "nct_id": "NCT04624230",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-04-14",
|
| "conditions": "Ulcerative Colitis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "tofacitinib",
|
| "nct_id": "NCT06020144",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-01-15",
|
| "conditions": "Rheumatoid Arthritis",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Hangzhou Highlightll Pharmaceutical Co., Ltd",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "tradipitant",
|
| "nct_id": "NCT07446439",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-12-01",
|
| "conditions": "Nausea and Vomiting; Obesity",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Vanda Pharmaceuticals",
|
| "company_name": "Vanda Pharmaceuticals Inc.",
|
| "ticker": "VNDA"
|
| },
|
| {
|
| "asset": "tulisokibart",
|
| "nct_id": "NCT06052059",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-08-01",
|
| "conditions": "Ulcerative Colitis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "tulisokibart",
|
| "nct_id": "NCT06052059",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-08-01",
|
| "conditions": "Ulcerative Colitis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "tulisokibart",
|
| "nct_id": "NCT06430801",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-10-30",
|
| "conditions": "Crohn's Disease",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "tulisokibart",
|
| "nct_id": "NCT06430801",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-10-30",
|
| "conditions": "Crohn's Disease",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "tulisokibart",
|
| "nct_id": "NCT06651281",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2037-12-17",
|
| "conditions": "Crohn Disease; Colitis, Ulcerative",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Merck Sharp & Dohme LLC",
|
| "company_name": "Merck & Co., Inc.",
|
| "ticker": "MRK"
|
| },
|
| {
|
| "asset": "utomilumab",
|
| "nct_id": "NCT05059522",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-12-31",
|
| "conditions": "Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "vepdegestrant",
|
| "nct_id": "NCT05654623",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2025-01-31",
|
| "conditions": "Advanced Breast Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "vepdegestrant",
|
| "nct_id": "NCT05909397",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-12-30",
|
| "conditions": "Breast Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Pfizer",
|
| "company_name": "PFIZER INC",
|
| "ticker": "PFE"
|
| },
|
| {
|
| "asset": "zanidatamab",
|
| "nct_id": "NCT05152147",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2026-07-31",
|
| "conditions": "Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Jazz Pharmaceuticals",
|
| "company_name": "Jazz Pharmaceuticals plc",
|
| "ticker": "JAZZ"
|
| },
|
| {
|
| "asset": "zanidatamab",
|
| "nct_id": "NCT05615818",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-06",
|
| "conditions": "Biliary Tract Neoplasms",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "UNICANCER",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "zanidatamab",
|
| "nct_id": "NCT06282575",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-12-01",
|
| "conditions": "Biliary Tract Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Jazz Pharmaceuticals",
|
| "company_name": "Jazz Pharmaceuticals plc",
|
| "ticker": "JAZZ"
|
| },
|
| {
|
| "asset": "zanidatamab",
|
| "nct_id": "NCT06435429",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-04-28",
|
| "conditions": "Metastatic HER2-positive Breast Cancer",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Jazz Pharmaceuticals",
|
| "company_name": "Jazz Pharmaceuticals plc",
|
| "ticker": "JAZZ"
|
| },
|
| {
|
| "asset": "zanubrutinib",
|
| "nct_id": "NCT03336333",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2021-05-07",
|
| "conditions": "Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "BeiGene",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "zanubrutinib",
|
| "nct_id": "NCT04002297",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-03",
|
| "conditions": "Mantle Cell Lymphoma; Non-Hodgkin Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "BeOne Medicines",
|
| "company_name": "BeOne Medicines Ltd.",
|
| "ticker": "ONC"
|
| },
|
| {
|
| "asset": "zanubrutinib",
|
| "nct_id": "NCT04170283",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-11",
|
| "conditions": "B-cell Malignancies",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "BeiGene",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "zanubrutinib",
|
| "nct_id": "NCT04662255",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-01",
|
| "conditions": "Lymphoma, Mantle-Cell",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Loxo Oncology, Inc.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "zanubrutinib",
|
| "nct_id": "NCT05100862",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2028-07",
|
| "conditions": "Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "BeOne Medicines",
|
| "company_name": "BeOne Medicines Ltd.",
|
| "ticker": "ONC"
|
| },
|
| {
|
| "asset": "zanubrutinib",
|
| "nct_id": "NCT06073821",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2032-02",
|
| "conditions": "CLL",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "BeOne Medicines",
|
| "company_name": "BeOne Medicines Ltd.",
|
| "ticker": "ONC"
|
| },
|
| {
|
| "asset": "zanubrutinib",
|
| "nct_id": "NCT06742996",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-08-31",
|
| "conditions": "Mantle Cell Lymphoma; B Cell Lymphoma",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "BeOne Medicines",
|
| "company_name": "BeOne Medicines Ltd.",
|
| "ticker": "ONC"
|
| },
|
| {
|
| "asset": "zanubrutinib",
|
| "nct_id": "NCT07277231",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2031-02",
|
| "conditions": "Chronic Lymphocytic Leukemia",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "BeOne Medicines",
|
| "company_name": "BeOne Medicines Ltd.",
|
| "ticker": "ONC"
|
| },
|
| {
|
| "asset": "zanubrutinib",
|
| "nct_id": "NCT07377578",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2031-05-30",
|
| "conditions": "Mantle Cell Lymphoma",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Guangzhou Lupeng Pharmaceutical Company LTD.",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "zasocitinib",
|
| "nct_id": "NCT06323356",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2025-10-15",
|
| "conditions": "Generalized Pustular Psoriasis; Erythrodermic Psoriasis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Takeda",
|
| "company_name": "TAKEDA PHARMACEUTICAL CO LTD",
|
| "ticker": "TAK"
|
| },
|
| {
|
| "asset": "zasocitinib",
|
| "nct_id": "NCT06550076",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2029-08-05",
|
| "conditions": "Plaque Psoriasis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Takeda",
|
| "company_name": "TAKEDA PHARMACEUTICAL CO LTD",
|
| "ticker": "TAK"
|
| },
|
| {
|
| "asset": "zasocitinib",
|
| "nct_id": "NCT06671483",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-05-18",
|
| "conditions": "Psoriatic Arthritis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Takeda",
|
| "company_name": "TAKEDA PHARMACEUTICAL CO LTD",
|
| "ticker": "TAK"
|
| },
|
| {
|
| "asset": "zasocitinib",
|
| "nct_id": "NCT06671496",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-05-18",
|
| "conditions": "Psoriatic Arthritis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Takeda",
|
| "company_name": "TAKEDA PHARMACEUTICAL CO LTD",
|
| "ticker": "TAK"
|
| },
|
| {
|
| "asset": "zasocitinib",
|
| "nct_id": "NCT07250802",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2033-01-24",
|
| "conditions": "Plaque Psoriasis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Takeda",
|
| "company_name": "TAKEDA PHARMACEUTICAL CO LTD",
|
| "ticker": "TAK"
|
| },
|
| {
|
| "asset": "zasocitinib",
|
| "nct_id": "NCT07250802",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2033-01-24",
|
| "conditions": "Plaque Psoriasis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Takeda",
|
| "company_name": "TAKEDA PHARMACEUTICAL CO LTD",
|
| "ticker": "TAK"
|
| },
|
| {
|
| "asset": "zasocitinib",
|
| "nct_id": "NCT07250802",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2033-01-24",
|
| "conditions": "Plaque Psoriasis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Takeda",
|
| "company_name": "TAKEDA PHARMACEUTICAL CO LTD",
|
| "ticker": "TAK"
|
| },
|
| {
|
| "asset": "zasocitinib",
|
| "nct_id": "NCT07250802",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2033-01-24",
|
| "conditions": "Plaque Psoriasis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Takeda",
|
| "company_name": "TAKEDA PHARMACEUTICAL CO LTD",
|
| "ticker": "TAK"
|
| },
|
| {
|
| "asset": "zasocitinib",
|
| "nct_id": "NCT07286058",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2029-12-18",
|
| "conditions": "Psoriatic Arthritis",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Takeda",
|
| "company_name": "TAKEDA PHARMACEUTICAL CO LTD",
|
| "ticker": "TAK"
|
| },
|
| {
|
| "asset": "ziltivekimab",
|
| "nct_id": "NCT05636176",
|
| "phase": "PHASE3",
|
| "status": "ACTIVE_NOT_RECRUITING",
|
| "primary_completion": "2027-07-02",
|
| "conditions": "Heart Failure",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novo Nordisk A/S",
|
| "company_name": "NOVO NORDISK A S",
|
| "ticker": "NVO"
|
| },
|
| {
|
| "asset": "ziltivekimab",
|
| "nct_id": "NCT06200207",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2026-10-01",
|
| "conditions": "Heart Failure; Systemic Inflammation",
|
| "arm_role": "active_comparator",
|
| "sponsor_raw": "Novo Nordisk A/S",
|
| "company_name": "NOVO NORDISK A S",
|
| "ticker": "NVO"
|
| },
|
| {
|
| "asset": "ziltivekimab",
|
| "nct_id": "NCT07276282",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-09-01",
|
| "conditions": "Coronary Artery Disease; Acute Myocardial Infarction (AMI); Coronary Atherosclerosis of Native Coronary Artery",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "ECRI bv",
|
| "company_name": null,
|
| "ticker": null
|
| },
|
| {
|
| "asset": "ziltivekimab",
|
| "nct_id": "NCT07301034",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2028-11-14",
|
| "conditions": "Myocardial Infarction",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Novo Nordisk A/S",
|
| "company_name": "NOVO NORDISK A S",
|
| "ticker": "NVO"
|
| },
|
| {
|
| "asset": "zodasiran",
|
| "nct_id": "NCT07037771",
|
| "phase": "PHASE3",
|
| "status": "RECRUITING",
|
| "primary_completion": "2027-08-20",
|
| "conditions": "Homozygous Familial Hypercholesterolemia",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Arrowhead Pharmaceuticals",
|
| "company_name": "ARROWHEAD PHARMACEUTICALS, INC.",
|
| "ticker": "ARWR"
|
| },
|
| {
|
| "asset": "zodasiran",
|
| "nct_id": "NCT07473843",
|
| "phase": "PHASE3",
|
| "status": "NOT_YET_RECRUITING",
|
| "primary_completion": "2028-07",
|
| "conditions": "Homozygous Familial Hypercholesterolemia",
|
| "arm_role": "experimental",
|
| "sponsor_raw": "Arrowhead Pharmaceuticals",
|
| "company_name": "ARROWHEAD PHARMACEUTICALS, INC.",
|
| "ticker": "ARWR"
|
| }
|
| ] |
